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V.

PFIZER, INC._______________
Defendant

I/We submit this application for transfer of the above-captioned case to the BCD, based on the following information:
Plaintiff
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STATE OF MAINE

Defendant
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•

.

.

□

.

□
□

1. Is at least one party a business entity?

[ 3 Yes

□

CD No

2. List all plaintiffs and their counsel:
COUNSEL (NAME AND ADDRESS)

PLAINTIFFfS)

STATE OF MAINE

E-MAIL ADDRESS

CAROLYN A. SILSBY
carolyn.silsby@maine.gov
Bar No. 3030
Assistant Attorney General
6 State House Station
Augusta, ME__04333-0006____

3. List all defendants and their counsel:
DEFENDANT(S)

PFIZER, INC.

COUNSEL (NAME AND ADDRESS)

E-MAIL ADDRESS

RUSSELL B. PIERCE, JR., ESQ m i e r ce@nhdlaw. com
Bar No. 7322
T
Norman. Hanson & DeTrov. LL(
415 Congress Street
_EJX_Box 4600, Part-land, ME.
04112

4. List any other cases with which this case is or may need be consolidated or coordinated:
CASE CAPTION

BCD-001

DOCKET NUMBER

CURRENT COURT LOCATION

5. What is the subject matter of the primary cause of action in this case:
□
□
□
□
□
□
□
□
□

Breach of Contract
Breach of Fiduciary Duty
80B Appeal involving a business entity
Internal governance of a business entity
Shareholder derivative action
Intellectual property
U.C.C. transactions
Antitrust or other trade regulations
Other (describe):

□
□
□
□
□
□

m
□

Breach of Warranty
Class Action
80C Appeal involving a business entity
Securities transactions
Confidential or trade secret
Financial transactions
Unfair trade practices
Commercial real estate

NOT YET
DETERMINED

6. What is the status of this case:
NO

YES
a. Has service of the complaint been completed on all
parties?...........................................................................
b. Are the pleadings closed? ....... . ..................................
c. Is discovery completed?................................................
d. Is class action status sought?....................................... .
e. Scheduled for trial? If so, w hen?.................................
f. Pretrial he ld ? ..................................................................
g Case management conference held? ......................... .
h. Jury trial? ....................................................................
i. Bench trial? ............:......... .......................................
j. ADR been attempted?...................................................
k. Is file sealed (partial / entire)?......................................
l. Will post-judgment judicial supervision be needed? ...
m. Consent Judgment tiled
7. What is the estimated length of trial (in days)? ___________

□

□
□
□
□
□
□
□
□
□
□
□
□

□
□
□
□
□
□
□
□
□
□
□
□

X

□

□
□

□
□
□
□
□

□
□
□

8. Identify nature and number of any pending pretrial motions:

9. Identify any novel and/or complex legal issues in this case:

10. Do all of the parties appearing in the case agree to a transfer?

[X] YES

□

NO

CERTIFICATION OF SERVICE BY ATTORNEY OR PARTY SUBMITTING APPLICATION
I hereby certify tfyit a copy was mailed/de livered to all counsel and pro se parties of record on this date
SIGNED:

C 'A ^ L A l t

(A

y

DATE
/

!

S

ORDER (For Bdt) Court Use Only)
The above Application having been considered, it is ORDERED as follows:
B ^ T h e case is ACCEPTED for transfer. The case file shall be transferred forthwith from the court in which the case is now
pending to the BCD.
I~~1 The case is NOT ACCEPTED for transfer.
DATE /

SIGNED (BCD Justice/Judge)

n
y-v-1-*
PLEASE NOTE THE FOLLOWING:
A. Failure to supply complete and accurate information may disqualify a case for consideration for transfer to
the BCD.
B. Information that does not fit on this form should be attached to a separate sheet and numbered to correspond
to the inquiries on the form.
C. This application should be filed with the court in which the case is currently pending.
BCD-001
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SUPERIOR COURT
CIVIL ACTION
DOCKET NO. CV-09-

STATE OF MAINE
KENNEBEC, SS

STATE OF MAINE,
Plaintiff,

)
)
)

v.

)

PFIZER INC.,
Defendant

CONSENTJUDGMENT

)
)
)
)

Plaintiff, the State of Maine, and Defendant, Pfizer Inc., voluntarily enter into this
Consent Judgment on the terms and conditions set forth below.
FINDINGS
A.

This Court has jurisdiction over the subject matter of this lawsuit and over all

B.

The terms of this Consent Judgment shall be governed by the laws of the State of

C.

Entry of this Consent Judgment is in the public interest and reflects a negotiated

Parties.

Maine.

agreement among the Parties.
D.

The Parties have agreed to resolve the issues related to the Covered Conduct

involving the prescription drug Geodon® by entering into this Consent Judgment.
E.

Pfizer is willing to enter into this Consent Judgment regarding the Covered

Conduct in order to resolve the Attorneys General’s concerns under the State Consumer

Protection Laws as to the matters addressed in this Consent Judgment and thereby avoid
unnecessary expense, inconvenience, and uncertainty.
F.

The Parties have agreed to resolve the issues raised by the Covered Conduct by

entering into this Consent Judgment.12
1.

Pfizer is entering into this Consent Judgment solely for the purpose of

settlement, and nothing contained herein may be taken as or construed to be an admission or
concession of any violation of law, rule, or regulation, or of any other matter of fact or law, or of
any liability or wrongdoing, all of which Pfizer expressly denies. Pfizer does not admit any
violation of the State Consumer Protection Laws set forth in footnote 1, and does not admit any
wrongdoing that was or could have been alleged by any Attorney General before the date of the
Consent Judgment under those laws. No part of this Consent Judgment, including its statements
and commitments, shall constitute evidence of any liability, fault, or wrongdoing by Pfizer. This
document and its contents are not intended for use by any third party for any purpose, including
submission to any court for any purpose.
2.

This Consent Judgment shall not be construed or used as a waiver or

limitation of any defense otherwise available to Pfizer in any action, or of Pfizer’s right to defend
itself from, or make any arguments in, any private individual, regulatory, governmental, or class
claims or suits relating to the subject matter or terms of this Consent Judgment. This Consent
Judgment is made without trial or adjudication of any issue of fact or law or finding of liability
of any kind. Notwithstanding the foregoing, a State may file an action to enforce the terms of
this Consent Judgment.

1 This agreement is entered into pursuant to and subject to the State Consumer Protection laws cited in footnote 2.
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3.

It is the intent of the Parties that this Consent Judgment not be admissible

in other cases or binding on Pfizer in any respect other than in connection with the enforcement
of this Consent Judgment.
4.

No part of this Consent Judgment shall create a private cause of action or

confer any right to any third party for violation of any federal or state statute except that a State
may file an action to enforce the terms of this Consent Judgment.

G.

This Consent Judgment (or any portion thereof) shall in no way be construed to

prohibit Pfizer from making representations with respect to Geodon® that are required under
Federal law or required under any Investigational New Drug Application, New Drug
Application, Supplemental New Drug Application, or Abbreviated New Drug Application
approved by the FDA.
H.

Nothing in this Consent Judgment shall require Pfizer to:
(a) take any action that is prohibited by the FDCA or any regulation promulgated

thereunder, or by FDA; or
(b) fail to take any action that is required by the FDCA or any regulation
promulgated thereunder, or by the FDA.

Any written or promotional claim subject to this

Consent Judgment which is the same, or materially the same, as the language required or agreed
to by the Director of Division of Drug Marketing, Advertising and Communication or the
Director of the Center for Drug Evaluation and Research or their authorized designees in writing
shall not constitute a violation of this Consent Judgment, unless facts are or become known to
Pfizer that cause the claim to be false, misleading or deceptive.
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DEFINITIONS
The following definitions shall be used in construing this Consent Judgment:
1.

“Author” shall mean an HCP or health care institution engaged to produce articles

or other publications relating to Geodon®.
2.

“Clinically Relevant Information” shall mean information that reasonably prudent

clinicians would consider relevant when making prescribing decisions regarding Geodon®.

3.

“Consultant” shall mean an HCP engaged for services other than for speaker

programs (e.g., as a member of an advisory board or to attend consultant meetings) that relate to
Promotional and Product Related Functions.
4.

“Covered Conduct” shall mean Pfizer’s promotional and marketing practices,

sampling practices, dissemination of information and remuneration to HCPs regarding the
prescription drug Geodon® through the Effective Date of the Agreement.

5.

“Effective Date” shall mean the date on which a copy of this Consent Judgment,

duly executed by Pfizer and by the Signatory Attorney General, is approved by, and becomes a
Consent Judgment of, the Court, whichever is later.

6.

“Geodon®” shall mean all Pfizer Products that are FDA-approved drug

formulations containing ziprasidone or ziprasidone mesylate.
7.

“Health Care Professional” or “HCP” shall mean any physician or other health

care practitioner who is licensed to provide health care services or to prescribe pharmaceutical
products.
4

8.

“Labeling” shall mean all FDA-approved labels, which are a display of written,

printed, or graphic matter upon the immediate container of any article, and other written, printed,
or graphic matters (a) upon any article or any of its containers or wrappers, or (b) accompanying
such article.
9.

“Medical Information Letter” shall mean a non-Promotional,

scientific

communication to address Unsolicited Requests for medical information from HCPs.
10.

“Medical Outcomes Specialists” shall mean Pfizer personnel who have expertise

working with managed care to determine suitable drugs on a formulary and are assigned to the
Medical Outcomes Specialist group of Pfizer.
11.

“Medical Reference Publication” shall have the meaning ascribed to the term

“reference publication” found in 21 C.F.R. 99.3(i).
12.

“Medical Science Liaison” shall mean a person, usually with an advanced

scientific degree (e . g a MD, PhD, or PharmD), assigned, employed, hired or retained by Pfizer
to provide scientific analysis and/or scientific information to HCPs and includes Regional
Medical Research Specialists.
13.

“Multistate Executive Committee” shall mean the Attorneys General and their

staffs representing Arizona, Colorado, Delaware, District of Columbia, Florida, Kentucky,
Maryland, Massachusetts, North Carolina, Ohio and Pennsylvania.
14.

“Multistate Working Group” shall mean the Attorneys General and their staff

representing Alabama, Arkansas, Arizona, California, Colorado, Connecticut, Delaware, District
5

of Columbia, Florida, Hawaii, Idaho, Illinois, Iowa, Kansas, Kentucky, Louisiana, Maine,
Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New
Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio,
Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont,
Washington, West Virginia, and Wisconsin.

15.

“Off-Label” shall mean a use not consistent with the indications section of the

Geodon® Labeling approved by the FDA at the time information regarding such use was
communicated.

16.

“Parties” shall mean Pfizer and the Signatory Attorney General.

17.

“Payment” is defined to include all payments or transfers of value (whether in

cash or in kind) made to physicians including all payments (including, for example, honoraria
payments, other payments, and reimbursement for lodging, travel and other expenses) made in
connection with physicians serving as speakers, participating in speaker training, or serving as
Consultants or Authors; payments or compensation for services rendered; grants; fees; payments
relating to research; payments relating to education; and payment or reimbursement for food,
entertainment, gifts, trips or travel, product(s)/item(s) provided for less than fair market value, or
other economic benefit paid or transferred. The term also includes all payments or transfers of
value made to Related Entities on behalf of, at the request of, for the benefit or use of, or under
the name of a physician for whom Pfizer would otherwise report a Payment if made directly to
the physician. The term “Payments” includes any Payments made, directly or indirectly, by
Pfizer to a physician or Related Entity in connection with, or under the auspices of, a co
promotion arrangement. The term “Payments” does not include: i) samples of drug products that
6

meet the definition set forth in 21 C.F.R. § 203.3(i), or ii) discounts, rebates, or other pricing
terms. Only for purposes of the reporting of Payments on March 31, 2011, the term “Payments”
does not include: i) individual Payments of less than $25 per instance, or ii) aggregate Payments
in a year to a physician or Related Entity of less than $500. Beginning with the March 31, 2012
report and all reports thereafter, individual Payments under $25 per instance and aggregate
Payments of less than $500 shall be included in the Payment amounts listed in the applicable
report.
18.

“Pfizer Inc.” or “Pfizer” shall mean Pfizer Inc., including all of its affiliates,

subsidiaries and divisions, predecessors, successors and assigns doing business in the United
States.
19.

“Pfizer Medical Education Grants Office” shall mean the U.S.-based organization

within Pfizer responsible for oversight of the continuing medical education (CME) grant process,
including the acceptance, review, and approval of all non-clinical CME grant requests.
20.

“Pfizer Marketing” shall mean Pfizer personnel assigned to the Pfizer U.S.

Geodon® marketing team(s).
21.

“Pfizer Medical” shall mean Pfizer personnel assigned to the Pfizer medical

organization.
22.

“Pfizer Sales” shall mean the Pfizer sales force responsible for U.S. Geodon®

sales, including but not limited to Medical Outcomes Specialists.
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23.

“Promotional,” “Promoting” or “Promote” shall mean claims about Geodon®

intended to increase sales or attempt to influence prescribing practices of HCPs, including directto-consumer as applicable.
24.

“Promotional and Product Related Functions”, includes: (a) the selling, detailing,

marketing, advertising, promoting, or branding of Geodon®; (b) the development, preparation,
or dissemination of materials or information about, or the provision of services relating to,
Geodon® including those functions relating to material review committees and Pfizer’s Medical
Information Department; and (c) research, development, and publication related-activities
involving Geodon®, including postmarketing and other studies, and the authorship, publication
and disclosure of study results.
25.

“Promotional Materials” shall mean any item with the product name, logo, or

message used to Promote Geodon®.
26.

“Promotional Slide Kit” shall mean Promotional Materials regarding Geodon® in

the form of a slide kit for use in speaker programs.
27.

“Promotional Speaker” shall mean a non-Pfizer employee HCP speaker used to

Promote Geodon®.
28.

“Related Entity” is any entity by or in which any physician receiving Payments is

employed, has tenure, or has an ownership interest.
29.

“Reprints Containing Off-Label Information” shall mean articles or reprints from

a peer reviewed journal or reference publication describing an Off-Label use of Geodon®.
8

B.

In Promotional Materials for Geodon®, Pfizer shall clearly and conspicuously

disclose the most serious risks associated with the product as set forth in the product’s labeling,
including information in any black box warning and shall present information about
effectiveness and information about risk in a balanced manner.
C.

Pfizer shall not Promote Geodon® for Off-Label uses.

D.

Pfizer shall not present patient profiles/types based on selected symptoms of the

FDA-approved indication(s) when Promoting Geodon®, unless:
1.

Geodon®’s specific FDA-approved indication(s) being Promoted is/are

stated clearly and conspicuously on the same page or on a facing page in any physical Promotional
Materials that reference the selected symptoms;

a.

With respect to Promotional Slide Kits or computer tablet based
Promotional Materials:
(i)

Pfizer shall state clearly and conspicuously the FDAapproved indication(s) on the same slide in which selected
symptoms are first presented;

(ii)

Pfizer shall include a short-hand reference to the statement
described in Section I.D.l.a.(i) on the same slide as each
subsequent reference to selected symptoms (e . g “See
complete list of FDA-approved indications at p. X”); and

10

30.

“Signatory Attorney General” shall mean the Attorney General of Maine, or her

authorized designee, who has agreed to this Consent Judgment.

31.

“State Consumer Protection Laws” shall mean the consumer protection laws

t
2
under which the Attorneys General have conducted the investigation.
32.

“Unsolicited Request” shall mean a request for information regarding Geodon®

from a non-Pfizer HCP communicated to an agent of Pfizer that has not been prompted.

COMPLIANCE PROVISIONS

I.

Promotional Activities
A.

Pfizer shall not make any written or oral claim that is false, misleading or

deceptive regarding Geodon®.2

2 ALABAMA - Alabama Deceptive Trade Practices Act, Ala. Code § 8-19-1 et seq.; ARIZONA - Arizona Consumer Fraud Act, A.R.S. § 441521 et seq:, ARKANSAS - Arkansas Deceptive Trade Practices Act, Ark. Code Ann. § 4-88-101, et seq:, CALIFORNIA - Bus. & Prof Code §§
17200 et seq. and 17500 et seq:, COLORADO - Colorado Consumer Protection Act, Colo. Rev. Stat. § 6-1-101 et seq:, DELAWARE Delaware Consumer Fraud Act, Del. CODE ANN. tit. 6, §§ 2511 to 2527; DISTRICT OF COLUMBIA, District o f Columbia Consumer
Protection Procedures Act, D.C. Code §§ 28-3901 et seq:, FLORIDA - Florida Deceptive and Unfair Trade Practices Act, Part II, Chapter 501,
Florida Statutes, 501.201 et seq:, HAWAII - Uniform Deceptive Trade Practice Act, Haw. Rev. Stat. Chpt 481A and Haw 501.201 et seq:,
IDAHO - Consumer Protection Act, Idaho Code Section 48-601 et seq:, ILLINOIS - Consumer Fraud and Deceptive Business Practices Act,
815 ILCS 505/2 et seq.; IOWA - Iowa Consumer Fraud Act, Iowa Code Section 714.16; KANSAS - Kansas Consumer Protection Act, K.S.A.
50-623 et seq. KENTUCKY - Kentucky Consumer Protection Act, KRS Ch. 367.110, et seq,; LOUISIANA - Unfair Trade-Practices and
Consumer Protection Law, LSA-R.S. 51:1401, el seq.; MAINE - Unfair Trade Practices Act, 5 M.R.S.A § 207 et seq.; MARYLAND Maryland Consumer Protection Act, Md. Code Ann., Com. Law §§ 13-101 et seq ; MASSACHUSETTS - Mass. Gen. Laws c. 93A, §§ 2 and 4;
MICHIGAN - Michigan Consumer Protection Act, MCL § 445.901 et seq.; MINNESOTA - Minnesota Deceptive Trade Practices Act, Minn.
Stat. §§ 325D.43-48; Minnesota False Advertising Act, Minn. Stat. § 325F.67; Minnesota Consumer Fraud Act, Minn Stat §§ 325F.68-70;
Minnesota Deceptive Trade Practices Against Senior Citizens or Disabled Persons Act, Minn. Stat ij 325F.71.; MISSOURI - Missouri
Merchandising Practices Act, Mo. Rev. Stat. §§ 407 et seq.; MONTANA - Montana Code Annotated 30-14-101 et seq.; NEBRASKA - Uniform
Deceptive Trade Practices Act, NRS §§ 87-301 et seq.; NEVADA - Deceptive Trade Practices Act, Nevada Revised Statutes 598.0903 et seq.;
NEW JERSEY - New Jersey Consumer Fraud Act, NJSA 56:8-1 et seq.; NEW MEXICO - NMSA 1978, § 57-12-1 et seq.; NEW YORK General Business Law Art. 22-A, §§ 349-50, and Executive Law § 63(12); NORTH CAROLINA - North Carolina Unfair and Deceptive Trade
Practices Act, N.C G.S 75-1.1, el seq.; NORTH DAKOTA - Unlcnvful Sates or Advertising Practices, N.D. Cent. Code § 51-15-02 et seq.;
OHIO —Ohio Consumer Sales Practices Act, R.C. 1345.01, et seq.; OREGON - Oregon Unlawful Trade Practices Act, Or. Rev, Stat. § 646.605
et seq.; PENNSYLVANIA - Pennsylvania Unfair Trade Practices and Consumer Protection Law, 73 P.S 201-1 el seq.; SOUTH CAROLINA South Carolina Unfair Trade Practices Act, sections 39-5-10 et seq.; SOUTH DAKOTA —South Dakota Deceptive Trade Practices and
Consumer Protection, SDCL ch. 37-24; TENNESSEE - Tennessee Consumer Protection Act, Tenn Code Ann, 47-18-101 et seq.; TEXAS Texas Deceptive Trade Practices-Consumer Protection Act, Tex Bus And Com Code 17.47, et seq.; VERMONT - Consumer Fraud Act, 9
V.S.A. §§ 2451 et seq ; WASHINGTON - Unfair Business Practices/Consumer Protection Act, RCW §§ 19.86 et seq.; WEST VIRGINIA West Virginia Consumer Credit and Protection Act, W. Va. Code § 46A-1101 et seq.; WISCONSIN - Wis. Stat. § 100.18 (Fraudulent
Representations).
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b.

With respect to Promotional Slide Kits, Pfizer shall require any
presenter of Pfizer’s Promotional Slide Kits to present the
statements required in Section I.D. 1.a.(i), as part of the mandatory
slides.

2.

Promotional

Materials have a reference indicating that the full

constellation of symptoms and the relevant diagnostic criteria are available in the Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV or current version), where applicable.

E.

Pfizer shall ensure that all Promotional Speakers’ Promotional Materials for

Geodon® comply with Pfizer’s obligations in the above Sections I.A. - D.
F.

Pfizer shall not award prizes or other incentives to its sales force as rewards for

the Off-Label sales or use of Geodon®.

II.

Dissemination and Exchange of Medical Information
A.

The content of Pfizer’s communications concerning Off-Label uses of Geodon®

shall not be false, misleading or deceptive.

B.

Medical Information Letters
1.

The following subsections shall be effective for nine years from the

Effective Date of this Consent Judgment.
2.

Pfizer Medical shall have ultimate responsibility for developing and

approving the medical content for all Medical Information Letters regarding Geodon®, including

any that may describe Off-Label information. Additional approvals may be provided by Pfizer’s
legal department. Pfizer shall not distribute any such materials unless:
a.

Clinically Relevant Information is included in these materials to
provide scientific balance;

b.

Data in these materials are presented in an unbiased, nonPromotional manner; and

c.

These materials are clearly distinguishable from sales aids and
other Promotional Materials.

3.

Pfizer Sales and Pfizer Marketing personnel shall not develop the medical

content of Medical Information Letters regarding Geodon®. This provision does not prohibit
Pfizer Sales or Pfizer Marketing personnel from suggesting topics for Medical Information
Letters.
4.

Pfizer Sales and Pfizer Marketing personnel shall not distribute Medical

Reference Publications or Medical Information Letters regarding Geodon®.

5.

Pfizer shall not knowingly disseminate any Medical Information Letter

describing any Off-Label use o f Geodon® that makes any false, misleading or deceptive
representation regarding Geodon® or any false, misleading or deceptive statement concerning a
competing product.
C.

Responses to Unsolicited Requests for Off-Label Information

12

1.

The following subsections shall be effective for nine years from the

Effective Date of this Consent Judgment.
2.

In responding to an Unsolicited Request for Off-Label information

regarding Geodon®, including any request for a specific article related to Off-Label uses, Pfizer
shall advise the requestor that the request concerns an Off-Label use and inform the requestor of
the drug’s FDA-approved indication(s) and/or dosage and other relevant Labeling information.

3.

If Pfizer elects to respond to an Unsolicited Request for Off-Label

information from a HCP regarding Geodon®, Pfizer Medical personnel shall provide specific,
accurate, objective, and scientifically balanced responses. Any such response shall not Promote
Geodon® for any Off-Label use(s).
4.

Any written response to an Unsolicited Request for Off-Label information

regarding Geodon® shall include:
a.

an existing Medical Information Letter prepared in accordance
with Section II.B;

b.

a Medical Information Letter or other document prepared in
response to the request in accordance with Section II.B; or

c.

a report containing the results of a reasonable literature search
using terms from the request.

5.

Pfizer Sales and Pfizer Marketing personnel may respond in writing to an

Unsolicited Request for Off-Label information regarding Geodon® from an HCP only by
13

informing the HCP of the presence or absence of published studies concerning the Off-Label
topic or by acknowledging whether the topic is an area of research, and by offering to request on
behalf of the HCP that a Medical Information Letter or other information be sent to the HCP in
follow up, provided it complies with sub-Section II.C.4 set forth above. Pfizer Sales and Pfizer
Marketing personnel shall not characterize, describe, identify, name, or offer any opinions about
or summarize any such Off-Label information.

Notwithstanding the foregoing, Medical

Outcomes Specialists may discuss in writing issues relating to pharmacoeconomics or health
outcomes with third party payors, including but not limited to managed care organizations and
employers responsible for the administration of health benefits, but not prescribers unless
employed or engaged by payors in a non-prescribing role.
6.

Pfizer Sales and Pfizer Marketing personnel may respond orally to an

Unsolicited Request for Off-Label information regarding Geodon® from an HCP only by
informing the HCP of the presence or absence of published studies concerning the Off-Label
topic or by acknowledging whether the topic is an area o f research, and by offering to request on
behalf of the HCP that a Medical Information Letter or other information be sent to the HCP in
follow up, provided it complies with sub-Section II.C.4 set forth above. Pfizer Sales and Pfizer
Marketing personnel shall not characterize, describe, identify, name, or offer any opinions about
or summarize any such Off-Label information.

Notwithstanding the foregoing, Medical

Outcomes Specialists may discuss orally issues relating to pharmacoeconomics or health
outcomes with third party payors, including but not limited to managed care organizations and
employers responsible for the administration of health benefits, but not prescribers unless
employed or engaged by payors in a non-prescribing role.
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D.

Reprints
1.

Pfizer shall not disseminate any information describing any Off-Label use

of Geodon® if such use has been submitted to the FDA for approval and the FDA has either
advised Pfizer that it refuses to approve such application or that FDA-identified deficiencies
must be resolved before approval can be granted unless Pfizer has first clearly and conspicuously
disclosed to the recipient of the information that the FDA had issued such advice regarding such
Off-Label use. Pfizer may disclose to any recipient of such information whether the information
was presented to the FDA prior to the FDA’s issuance of such advice regarding the Off-Label
use.
2.

Pfizer shall not disseminate a Medical Information Letter, an unabridged

reprint or copy of an article from a peer reviewed journal or a Reference Publication, or
written information through a Regional Medical Research Specialist (“RMRS”)
describing any Off-Label use of Geodon® in response to an Unsolicited Request unless:
a.

the information is about a clinical investigation with respect to
Geodon® and experts qualified by scientific training or experience
to evaluate the safety or effectiveness of Geodon® would consider
the subject of the clinical investigation to be scientifically sound or
the information is an unabridged reprint or copy of an article from
a peer reviewed journal or a Reference Publication;
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b.

the information is accompanied by a comprehensive bibliography
of publications discussing adequate and well-controlled clinical
studies published in a medical journal or medical or scientific text
that have been previously published about the use of Geodon®
covered by the information (unless the information is a peer
reviewed journal or Reference Publication which already includes
such a bibliography); and

c.

in cases in which experts qualified by scientific training or
experience to evaluate the safety or effectiveness of Geodon®
would consider the conclusion of the information to have been
specifically called into question by another article(s) or text(s) that
experts qualified by scientific training or experience to evaluate the
safety or effectiveness of Geodon® would consider to be
scientifically sound, the information must be disseminated with a
representative publication that reaches contrary or different
conclusions regarding the Off-Label use.

3.

Reprints Containing Off-Label Information
a.

Pfizer Medical shall be responsible for the identification, selection,
approval and dissemination of Reprints Containing Off-Label
Information regarding Geodon®.

b.

Reprints Containing Off-Label Information regarding Geodon®:
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(i) shall be accompanied by the full prescribing information
for the product and contain a disclosure in a prominent
location, which would include the first page or as a cover
page where practicable, indicating that the article may
discuss Off-Label information; and
(ii) shall not be referred to or used in a Promotional manner.
c.

Reprints Containing Off-Label Information regarding Geodon®
may only be disseminated by Pfizer Medical personnel to HCPs.
Pfizer Sales or Pfizer Marketing personnel shall not disseminate
these materials to HCPs, absent the exception described below in
(i); provided, however, that Medical Outcomes Specialists may
disseminate reprints relating to pharmacoeconomics or health
outcomes to third party payors, including but not limited to
managed care organizations and employers responsible for the
administration of health benefits, but not prescribes unless
employed or engaged by payors in a non-prescribing role.
(i)

In the event of an extraordinary circumstance in which
there is a clinical necessity to have Pfizer Sales or Pfizer
Marketing personnel disseminate a Reprint Containing OffLabel information directly to HCPs, the President of Pfizer
Worldwide Pharmaceutical Operations may approve a
Clinical Necessity Exception to the prohibition described in
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Section II.D.3.C above for that Reprint Containing OffLabel information.
(ii) If the Clinical Necessity Exception is invoked, Pfizer will
notify each Signatory Attorney General of its intent to
invoke the Clinical Necessity Exception at least 30 business
days

prior

to

representatives

disseminating
any

Reprint

through

Pfizer

Containing

sales

Off-Label

information on Geodon®.
(a) If a Signatory Attorney General believes the Reprint
Containing Off-Label information to be disseminated
does not meet the Clinical Necessity Exception, then
the State will provide Pfizer with written notice within
30 business days and provide Pfizer an opportunity to
discuss its desired use of the Reprint Containing OffLabel information pursuant to the limited exception.
(b) If the State and Pfizer do not come to a resolution, then
the State may initiate legal action to prevent the
dissemination of the Reprint Containing Off-Label
information

by Pfizer Sales

or Pfizer Marketing

personnel.
(c) If the State initiates legal action to prevent the
dissemination of the Reprint Containing Off-Label
information
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by Pfizer Sales

or Pfizer Marketing

personnel, Pfizer shall not use Pfizer Sales or Pfizer
Marketing personnel to disseminate such Reprint
Containing Off-Label information in that State until the
issue has been resolved.
4.

Nothing

in

this

Consent Judgment

shall

preclude

Pfizer

from

disseminating Reprints Containing Off-Label information which have an incidental reference to
Off-Label information. If reprints have an incidental reference to Off-Label information, such
reprints shall contain the disclosure required by Section II.D.3.b(i) in a prominent location, as
defined above.
5.

Pfizer shall not disseminate any reprint or copy o f an article from a peer

reviewed journal or a Medical Reference Publication describing any Off-Label use of Geodon®
to physician specialties that do not customarily prescribe Geodon® if these materials combined
with detailing, advertising, sampling, or other Promotional activities Promote Off-Label use of
Geodon®.
6.

In disseminating information about Off-label usage, Pfizer shall either

follow the substantive procedures in Section TV of the January, 2009, FDA guidance entitled
Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific
Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared
Medical Devices or use an alternative approach provided such approach satisfies the
requirements of the applicable statutes and regulations.
E.

Pfizer shall develop, implement and maintain policies and procedures to ensure

that Medical Science Liaisons do not promote Off-label uses of Geodon® and to ensure that they
do not engage in the improper marketing of Geodon®.
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III.

Continuing Medical Education (CME) and Grants
A.

The following subsections shall be effective for six years from the Effective Date

of this Consent Judgment.
B.

Pfizer shall disclose information about grants, including CME grants, regarding

Geodon® consistent with the current disclosures of the Pfizer Medical Education Grants Office
registry at hlip://www.pfizer.com/responsibility/grants pavments/medical education grants.isr)
(hereinafter, “Pfizer Medical Education Grants Office website”) or as required by applicable law.
1.

Once posted, Pfizer shall maintain this information on the Pfizer Medical

Education Grants Office website for at least two years and shall maintain the information in a
readily accessible format for review by the States upon written request for a period of five years.
C.

The Pfizer Medical Education Grants Office shall manage all requests for funding

related to CME relating to Geodon®. Approval decisions shall be made by the Pfizer Medical
Education Grants Office and Pfizer Medical, and shall be kept separate from the Pfizer Sales and
Pfizer Marketing organizations.
D.

Pfizer shall not use grants to Promote Geodon®. This provision includes, but is

not limited to, the following prohibitions:
1.

Pfizer Sales and Pfizer Marketing personnel shall not initiate, coordinate

or implement grant applications on behalf of any customer or HCP;
2.

Pfizer Sales and Pfizer Marketing personnel shall not be involved in

selecting grantees or CME-funded speakers; and
3.

Pfizer Sales and Pfizer Marketing personnel shall not measure or attempt

to track in any way the impact of grants or speaking fees on the participating HCPs’ subsequent
prescribing habits, practices or patterns.
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E.

Pfizer shall not condition funding of a CME program grant request relating to

Geodon® upon the requestor’s selection or rejection of particular speakers.
F.

Pfizer shall not suggest, control, or attempt to influence selection of the specific

topic, title, content, speakers or audience for CMEs relating to Geodon®, consistent with
ACCME guidelines.
G.

Pfizer Sales and Pfizer Marketing personnel shall not approve grant requests

regarding Geodon®, nor attempt to influence the Pfizer Medical Education Grants Office to
reward any customers or HCPs with grants for their prescribing habits, practices or patterns.
H.

Pfizer shall contractually require the CME provider to disclose to CME program

attendees Pfizer’s financial support of the CME program and any financial relationship with
faculty and speakers at such CME.
I.

After the initial delivery of a CME program, Pfizer shall not fund the same

program, nor shall it provide additional funding for re-distribution of the same program, if Pfizer
Medical Education Grants Office or Pfizer Medical knows that the program’s speakers are
Promoting Geodon® for Off-Label uses, unless it takes specific action that ensures that such
Promotion does not occur.
IV.

Payments to Speakers and HCPs
A.

On or before March 31, 2011, Pfizer shall post in a prominent position on its

website an easily accessible and readily searchable listing of all U.S.-based physicians, and
Related Entities who or which received Payments directly or indirectly from Pfizer between July
1, 2010 and December 31, 2010 and the aggregate value of such Payments.
B.

After the initial posting, Pfizer shall post annual listings on March 31, 2012 and

March 31 of each of the three successive years. The annual listing on March 31, 2012 and
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thereafter shall include cumulative information about Payments made by Pfizer during each of
the respective prior calendar years.
C.

In addition, beginning on June 1, 2012, Pfizer shall include on its website a listing

of all U.S. based physicians and Related Entities who or which received Payments from Pfizer
during the first calendar quarter of 2012. Thereafter, 60 days after the end of each subsequent
calendar quarter, Pfizer shall also post on its website a listing of updated information about all
Payments provided during the preceding quarters) in each calendar year. The quarterly and
annual reports shall be easily accessible and readily searchable.
D.

Each listing made pursuant to this section shall include a complete list of all

individual physicians, and/or Related Entities to whom or to which Pfizer directly or indirectly
made Payments in the preceding calendar year for 2011 and after June 1, 2012 for the preceding
quarter or year (as applicable). Each listing shall be arranged alphabetically according to the
physicians’ last name or the name of the Related Entity. The Payment amounts in the lists shall
be reported in $10,000 increments (e.g., $0 - $10,000; $10,001- $20,000; etc.) or in the actual
amount paid, provided, however, that the Payment amounts shall be listed in the same way
(incrementally or in actual amounts) for all physicians and/or Related Entities on the listing. For
each physician, the applicable listing shall include the following information: i) physician’s full
name; ii) name of any Related Entities (if applicable); iii) city and state that the physician or
Related Entity has provided to Pfizer for contact purposes; and (iv) the aggregate value of the
Payment(s) in the preceding quarter(s) or year (as applicable).

If Payments for multiple

physicians have been made to one Related Entity, the aggregate value of all Payments to the
Related Entity will be the reported amount.
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E.

Pfizer shall continue to make each annual listing and the most recent quarterly

listing of Payments available on its website at least through March 31, 2014. Pfizer shall retain
and make available to the State, upon request, all work papers, supporting documentation,
correspondence, and records related to all applicable Payments and to the annual and quarterly
listings of Payments. Nothing in this section affects the responsibility of Pfizer to comply with
(or liability for noncompliance with) all applicable Federal health care program requirements and
state laws as they relate to all applicable Payments made to physicians or Related Entities.
F.

If the proposed Physician Payments Sunshine Act of 2009 or similar legislation is

enacted, the State shall determine whether the purposes of this section are reasonably satisfied by
Pfizer’s compliance with such legislation. In such case, and in its sole discretion, the State may
agree to modify or terminate provisions of this section as appropriate.
G.

The term “physician” as used in this section does not include bona-fide employees

of Pfizer or its subsidiaries.
H.

Pfizer’s posting of Payment information shall be subject to any applicable

confidentiality provisions contained in clinical research agreements that were entered with a
U. S.-based physician prior to July 1, 2009. Pfizer agrees that it shall not include any such
confidentiality provisions in any new or renewed clinical research agreements entered after the
Effective Date of this Consent Judgment that require any Payment to a U.S.-based physician.
V.

Product Samples
A.

The following subsections shall be effective for nine years from the Effective

Date of this Consent Judgment.
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B.

Pfizer shall only provide samples of Geodon® to those HCPs who have

specialties that customarily treat patients who have diseases for which treatment with Geodon®
would be consistent with Geodon®’s Labeling.
C.

If a HCP whose clinical practice is inconsistent with the product’s Labeling

requests samples, Pfizer personnel shall refer the practitioner to 1-800-438-1985 where the
practitioner can speak directly with a Pfizer representative who will provide answers to the
HCP’s questions about Geodon® and may provide them with samples only if appropriate (i.e., if
the physician requests the sample for an on-label use).
D.

Pfizer shall not disseminate samples of Geodon® with the intent of increasing

Off-Label prescribing of Geodon®.
VI.

Clinical Research
A.

Pfizer shall report research regarding Geodon® in an accurate, objective and

balanced manner as follows and as required by applicable law:
1.

To the extent permitted by the National Library of Medicine and as

required by the FDA Amendments Act (Public Law No. 110-85), Pfizer shall register clinical
trials and submit results to the registry and results data bank regarding Geodon® as required by
the FDA Amendments Act and any accompanying regulations that may be promulgated pursuant
to that Act. With respect to Geodon®, Pfizer shall register on a publicly accessible website all
Pfizer-sponsored Phase II, III and IV clinical trials, to the extent available, that were ongoing or
initiated after July 1, 2005 and will post results on a publicly accessible website of all Pfizersponsored Phase II, III and IV clinical trials, to the extent available, that were completed after
October 2002.
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B.

When presenting information about a clinical study regarding Geodon® in any

Promotional Materials, Pfizer shall not do any of the following:
1.

present favorable information or conclusions from a study that is

inadequate in design, scope, or conduct to furnish significant support for such information or
conclusions;
2.

use the concept of statistical significance to support a claim that has not

been demonstrated to have clinical significance or validity, or fails to reveal the range of
variations around the quoted average results;
3.

use statistical analyses and techniques on a retrospective basis to discover

and cite findings not soundly supported by the study, or to suggest scientific validity and rigor
for data from studies the design or protocol of which are not amenable to formal statistical
evaluations;
4.

present the information in a way that implies that the study represents

larger or more general experience with the drug than it actually does; or
5.

use statistics on numbers of patients, or counts of favorable results or side

effects, derived from pooling data from various insignificant or dissimilar studies in a way that
suggests either that such statistics are valid if they are not or that they are derived from large or
significant studies supporting favorable conclusions when such is not the case.
VII.

Terms Relating to Payment
A.

No later than 30 days after the Effective Date of this Order, Pfizer shall pay a total

amount of $33 million to be divided and paid by Pfizer directly to each Signatory Attorney
General of the Multistate Working Group in an amount to be designated by and in the sole
discretion of the Multistate Executive Committee. Said payment shall be used by the States as
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and for attorneys’ fees and other costs of investigation and litigation, or to be placed in, or
applied to, the consumer protection enforcement fund, including future consumer protection
enforcement, consumer education, litigation or local consumer aid fund or revolving fund, used
to defray the costs of the inquiry leading hereto, and may be used to fund or assist in funding
programs directed at mental illness treatment, including but not limited to education and outreach
or for other uses permitted by state law, at the sole discretion of each Signatory Attorney
General. The Parties acknowledge that the payment described herein is not a fine penalty, or
payment in lieu thereof.
VIII.

Release
A.

By its execution of this Consent Judgment, the State of Maine releases Pfizer and

all of its past and present subsidiaries, affiliates, predecessors and successors (collectively, the
“Released Parties”) from the following: all civil claims, causes of action, damages, restitution,
fines, costs, and penalties that the Maine Attorney General could have asserted against the
Released Parties under the above-cited consumer protection statutes resulting from the Covered
Conduct up to and including the Effective Date that is the subject of this Consent Judgment.
B.

Notwithstanding any term of this Consent Judgment, specifically reserved and

excluded from the Release in Paragraph VIII.A. as to any entity or person, including Released
Parties, are any and all of the following:
1.

Any criminal liability that any person and/or entity, including Released

Parties, has or may have to the State of Maine.
2.

Any civil or administrative liability that any person and/or entity,

including Released Parties, has or may have to the State of Maine not expressly covered by the
release in Paragraph (A) above, including but not limited to any and all of the following claims:
26

a)

State or federal antitrust violations;

b)

Reporting practices, including “best price”, “average wholesale
price” or “wholesale acquisition cost;”

c)

Medicaid violations, including federal Medicaid drug rebate statute
violations, Medicaid fraud of abuse, and/or kickback violations
related to any State’s Medicaid program; and,

d)
3.

State false claims violations.

Any liability under the State of Maine’s above-cited consumer protection

laws which any person and/or entity, including Released Parties, has or may have to individual
consumers or State program payors of said State.
4.

Any liability for failure to comply with Maine’s Prescription Drug Clinical

Trial Reporting Rule: DHS Rule 10-144 Ch. 275, AG Rule 26-0259 Ch. 11 with respect to any
drug other than Geodon.
IX

Nothing contained in this Judgment Order shall relieve or release Pfizer o f the obligations

it maintains under any other Consent Judgment or agreement relating to any Pfizer product.
X.

Dispute Resolution

A.

For the purposes of resolving disputes with respect to compliance with this

Consent Judgment, should any of the Signatory Attorneys General have a reasonable basis to
believe that Pfizer has engaged in a practice that violates a provision of this Consent Judgment
subsequent to the Effective Date of this Judgment, then such Attorney General shall notify Pfizer
in writing of the specific objection, identify with particularity the provisions of this Consent
Judgment that the practice appears to violate, and give Pfizer thirty (30) days to respond to the
notification; provided, however, that a Signatory Attorney General may take any action if the
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Signatory Attorney General concludes that, because of the specific practice, a threat to the health
or safety of the public requires immediate action. Upon receipt of written notice, Pfizer shall
provide a good-faith written response to the Attorney General notification, containing either a
statement explaining why Pfizer believes it is in compliance with the Consent Judgment, or a
detailed explanation of how the alleged violation occurred and a statement explaining how Pfizer
intends to remedy the alleged breach. Nothing in this paragraph shall be interpreted to limit the
state’s Civil Investigative Demand (“CID”) or investigative subpoena authority, to the extent
such authority exists under applicable state law, and Pfizer reserves all of its rights with respect
to a CID or investigative subpoena issued pursuant to such authority.
B.

Upon giving Pfizer thirty (30) days to respond to the notification described above,

the Signatory Attorney General shall also be permitted reasonable access to inspect and copy
relevant, non-privileged, non-work product records and documents in the possession, custody or
control of Pfizer that relate to Pfizer’s compliance with each provision of this Consent Judgment
as to which cause that is legally sufficient in the State has been shown. If the Signatory Attorney
General makes or requests copies of any documents during the course of that inspection, the
Signatory Attorney General will provide a list of those documents to Pfizer.
C.

The State may assert any claim that Pfizer has violated this Consent Judgment in a

separate civil action to enforce compliance with this Consent Judgment, or may seek any other
relief afforded by law, but only after providing Pfizer an opportunity to respond to the
notification described in Paragraph X.A. above; provided, however, that a Signatory Attorney
General may take any action if the Signatory Attorney General concludes that, because of the
specific practice, a threat to the health or safety of the public requires immediate action.
XI.

General Provisions
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A.

This Consent Judgment represents the full and complete terms of the settlement

entered into by the Parties hereto. In any action undertaken by the Parties, no prior versions of
this Consent Judgment and no prior versions of any of its terms that were not entered by the
Court in this Consent Judgment, may be introduced for any purpose whatsoever.
B.

This Court retains jurisdiction of this Consent Judgment and the Parties hereto for

the purpose of enforcing and modifying this Consent Judgment and for the purpose of granting
such additional relief as may be necessary and appropriate.
C.

This Consent Judgment may be executed in counterparts, and a facsimile or PDF

signature shall be deemed to be, and shall have the same force and effect as, an original
signature.
D.

All Notices under this Order shall be provided to the following via Overnight

Mail:
For the State of Maine:

Chief, Consumer Protection Division
Office of the Maine Attorney General
6 State House Station
Augusta, ME 04333-0006

For Pfizer Inc.:

Douglas M. Lankier
Senior Vice President
And Chief Compliance Officer
Pfizer Inc.
150 East 42nd Street
New York, New York 10017

E.

To the extent that any provision o f this Consent Judgment obligates Pfizer to

change any policy(ies) or procedure(s) and to the extent not already accomplished, Pfizer shall
implement the policy(ies) or procedure(s) as soon as reasonably practicable, but no later than 120
days after the Effective Date of this Consent Judgment.
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IT IS HEREBY ORDERED, ADJUDGED AND DECREED.

Dated: _____________________

__________________
JUSTICE
Maine Superior Court

For Plaintiff:

JANET T. MILLS
ATTORNEY GENERAL

Dated: September 2 ., 2009
CAROLYN AUS1LSBY, Bar No. 303£
ASSISTANT ATTORNEY GENERAT
Office of the Maine Attorney General
6 State House Station
Augusta, ME 04333-0006
(207)626-8829
Carolyn.silsby@maine.gov
ATTORNEYS FOR THE STATE OF MAINE
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For Defendant:

Dated: September 2_ , 2009
RUSSELL B. PIERCE, JR, Bar No.
Norman, Hanson & DeTroy, LLC
415 Congress Street
P;0. Box 4600
Portland, ME 04112-4600
(207) 774 7000
ATTORNEY FOR PFIZER INC.
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For Pfizer Inc,:

Douglas M, Lankier
Senior Vice President
And Chief Compliance Officer
Pfizer Inc.
Dale:

By:

By:

Robert P. Sherman
DLA Piper LLP (US)
33 Arch Street, 26th Floor
Boston, MA 02110

Bnen T. O’Connor
Ropes & Gray
One International Place
Boston, MA 02 ![10
Date:
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STATE OF MAINE,
)
)
)
)
)
)
)
)

Plaintiff,
v.
PFIZER INC.,
Defendant

CONSENT JUDGMENT

Plaintiff, the State o f Maine, and Defendant, Pfizer Inc., voluntarily enter into this
Consent Judgment on the terms and conditions set forth below,
FINDINGS
A.

This Court has jurisdiction over the subject matter o f this lawsuit and over all

B.

The terms o f this Consent Judgment shall be governed by the laws o f die State of

C.

Entry o f this Consent Judgment is in the public interest and reflects a negotiated

Parties.

Maine.

agreement among the Parties.
D.

The Parties have agreed to resolve the issues related to the Covered Conduct

involving the prescription drug Geodon® by entering into this Consent Judgment.
E.

Pfizer is willing to enter into this Consent Judgment regarding the Covered

Conduct in order to resolve the Attorneys General’s concerns under the State Consumer

1

Protection Laws as to the matters addressed in this Consent Judgment and thereby avoid
unnecessary expense, inconvenience, and uncertainty.
F.

The Parties have agreed to resolve the issues raised by the Covered Conduct by

entering into this Consent Judgment;12
I.

Pfizer is entering into this Consent Judgment solely for the purpose of

settlement, and nothing contained herein may be taken as or construed to be an admission or
concession o f any violation o f law, rule, or regulation, or of any other matter o f fact or law, or o f
any liability or wrongdoing, all o f which Pfizer expressly denies. Pfizer does not admit any
violation o f the State Consumer Protection Laws set forth in footnote 1, and does not admit any
' wrongdoing that was or could have been alleged by any Attorney General before the date o f the
Consent Judgment under those laws. No part o f this Consent Judgment, including its statements
and commitments, shall constitute evidence o f any liability, fault, or wrongdoing by Pfizer. This
document and its contents are not intended for use by any third party for any purpose, including
submission to any court for any purpose.
2.

,

This Consent Judgment shall not be construed or used as a waiver or

limitation o f any defense otherwise available to Pfizer in any action, or o f Pfizer’s right to defend
itself from, or make any arguments in, any private individual, regulatory, governmental, or class
claims or suits relating to the subject matter or terms o f this Consent Judgment. This Consent
Judgment is made without trial or adjudication o f any issue o f fact or law or finding o f liability
o f any kind. Notwithstanding the foregoing, a State may file an action to enforce the terms of
this Consent Judgment.

1This agreement is entered into pursuant to and subject to the State Consumer Protection laws cited in footnote 2.
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3.

It is the intent o f the Parties that this Consent Judgment not be admissible

in other cases or binding on Pfizer in any respect other than in connection with the enforcement
o f this Consent Judgment.
4.

No part o f this Consent Judgment shall create a private cause o f action or

confer any right to any third party for violation o f any federal or state statute except that a State
may file an action to enforce the terms of this Consent Judgment.

G.

This Consent Judgment (or any portion thereof) shall in no way be construed to

prohibit Pfizer from making representations with respect to Geodon® that are required under
Federal law or required under any Investigational New Drug Application, New Drug
Application, Supplemental New Drug Application, or Abbreviated New Drug Application
approved by the IDA.
H.

Nothing in this Consent Judgment shall require Pfizer to:
(a) take any action that is prohibited by the FDCA or any regulation promulgated

thereunder, or by FDA; or
(b) fail to take any action that is required by the FDCA or any regulation
promulgated thereunder, or by the FDA. Any written or promotional claim subject to this
Consent Judgment which is the same, or materially the same, as the language required or agreed
to by the Director o f Division o f Drug Marketing, Advertising and Communication or the
Director o f the Center for Drug Evaluation and Research or their authorized designees in writing
shall not constitute a violation o f this Consent Judgment, unless facts are or become known to
Pfizer that cause the claim to be false, misleading or deceptive.

3

DEFINITIONS

The following definitions shall be used in construing this Consent Judgment:

1.

“Author” shall mean an HCP or health care institution engaged to produce articles

or other publications relating to Geodon®.

2.

“Clinically Relevant Information” shall mean information that reasonably prudent

clinicians would consider relevant when making prescribing decisions regarding Geodon®.

3.

“Consultant” shall mean an HCP engaged for services other than for speaker

programs (e.g.. as a member o f an advisory board or to attend consultant meetings) that relate to
Promotional and Product Related Functions.
4.

“Covered Conduct” shall mean Pfizer’s promotional and marketing practices,

sampling practices, dissemination o f information and remuneration to HCPs regarding the
prescription drug Geodon® through the Effective Date o f the Agreement.

5.

“Effective Date” shall mean the date on which a copy o f this Consent Judgment,

duly executed by Pfizer and by the Signatory Attorney General, is approved by, and becomes a
Consent Judgment of, the Court, whichever is later.

6.

“Geodon®” shall mean all Pfizer Products that are FDA-approved drug

formulations containing ziprasidone or ziprasidone mesylate.

7.

“Health Care Professional” or “HCP” shall mean any physician or other health

care practitioner who is licensed to provide health care services or to prescribe pharmaceutical
products.
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8.

“Labeling" shall mean all FDA-approved labels, which are a display of written,

printed, or graphic matter upon the immediate container o f any article, and other written, printed,
or graphic matters (a) upon any article or any of its containers or wrappers, or (b) accompanying
such article.
9.

“Medical Information

Letter” shall mean a non-Promotional,

scientific

communication to address Unsolicited Requests for medical information from HCPs.
10.

“Medical Outcomes Specialists” shall mean Pfizer personnel who have expertise

working with managed care to determine suitable drugs on a formulary and are assigned to the
Medical Outcomes Specialist group o f Pfizer.

11.

“Medical Reference Publication” shall have the meaning ascribed to the term

“reference publication” found in 21 CJP.R. 99.3(i).

12.

“Medical Science Liaison” shall mean a person, usually with an advanced

scientific degree (e.g., a MD, PhD, or PharmD), assigned, employed, hired or retained by Pfizer
to provide scientific analysis and/or scientific information to HCPs and includes Regional
Medical Research Specialists.

13.

“Multistate Executive Committee” shall mean the Attorneys General and their

staffs representing Arizona, Colorado, Delaware, District o f Columbia, Florida, Kentucky,
Maryland, Massachusetts, North Carolina, Ohio and Pennsylvania
14.

“Multistate Working Group” shall mean the Attorneys General and their staff

representing Alabama, Arkansas, Arizona, California, Colorado, Connecticut, Delaware, District
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o f Columbia, Florida, Hawaii, Idaho, Illinois, Iowa, Kansas, Kentucky, Louisiana, Maine,
Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New
Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio,
Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee,. Texas, Vermont,
Washington, West Virginia, and Wisconsin.

15.

“Off-Label” shall mean a use not consistent with the indications section o f the

Geodon® Labeling approved by the FDA at the time information regarding such use was
communicated;
16.

“Parties” shall mean Pfizer and the S ignatory Attorney General.

17.

‘Tayraent” is defined to include all payments or transfers o f value (whether in

cash or in kind) made to physicians including all payments (including, for example* honoraria
payments, other payments, and reimbursement for lodging, travel and other expenses) made in
connection with physicians serving as speakers, participating in speaker training, or serving as
Consultants or Authors; payments or compensation for services rendered; grants; fees; payments
relating to research; payments relating to education; and payment or reimbursement for food,
entertainment, gifts, trips or travel, product(s)/item(s) provided for less than fair market valúe, or
other economic benefit paid or transferred. The term also includes all payments or transfers of
value made to Related Entities on behalf o f at the request of, for the benefit or use of, or under
the name o f a physician for whom Pfizer would otherwise report a Payment if made directly to
the physician. The term “Payments” includes any Payments made, directly or indirectly, by
Pfizer to a physician or Related Entity in connection with, or under the auspices of, a co
promotion arrangement. The term “Payments” does not include: i) samples o f drug products that

6

meet the definition set forth in 21 C.F.R. § 203.3(i), or ii) discounts, rebates, or other pricing
terms. Only for purposes o f the reporting o f Payments on March 31,2011, the term “Payments”
does not include: i) individual Payments o f less than $25 per instance, or ii) aggregate Payments
in a year to a physician of Related Entity o f less than $500. Beginning with the March 31, 2012
report and all reports thereafter, individual Payments under $25 per instance and aggregate
Payments o f less than $500 shall be included in the Payment amounts listed in the applicable
report.
18.

“Pfizer Iric.” or “Pfizer” shall mean Pfizer Inc., including all o f its affiliates,

subsidiaries and divisions, predecessors, successors and assigns doing business in the United
States.
19.

“Pfizer Medical Education Grants Office” shall mean the U.S.-based organization

within Pfizer responsible for oversight of the continuing medical education (CME) grant process,
including the acceptance, review, and approval o f all non-clinical CME grant requests.

20.

“Pfizer Marketing” shall mean Pfizer personnel assigned to the Pfizer U.S.

Geodon® marketing team(s).

21.

‘Tfizer Medical” shall mean Pfizer personnel assigned to the Pfizer medical

organization.

22.

“Pfizer Sales” shall mean the Pfizer sales force responsible for U.S. Geodon®

sales, including but not limited to Medical Outcomes Specialists.
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23.

“Promotional,” “Promoting” or “Promote” shall mean claims about Geodon®

intended to increase sales or attempt to influence prescribing practices of HCPs, including directto-consumer as applicable.

24.

“Promotional and Product Related Functions” includes: (a) the selling, detailing,

marketing, advertising, promoting, or branding o f Geodon®; (b) the development, preparation,
or dissemination o f materials or information about, or the provision o f services relating to,
Geodon® including those functions relating to material review committees and Pfizer’s Medical
Information Department; and (c) research, development, and publication related-activities
involving Geodon®, including postmarketing and other studies, and the authorship, publication
and disclosure o f study results.

25.

“Promotional Materials” shall mean any item with the product name, logo, or

message used to Promote Geodon®.

26.

“Promotional Slide Kit” shall mean Promotional Materials regarding Geodon® in

the form o f a slide kit for use in speaker programs.

27.

“Proinotional Speaker” shall mean a non-Pfizer employee HCP speaker used to

Promote Geodon®.

28.

“Related Entity” is any entity by or in which any physician receiving Payments is

employed, has tenure, or has an ownership interest.

29.

“Reprints Containing Off-Label Information” shall mean articles or reprints from

a peer reviewed journal or reference publication describing an Off-Label use o f Geodon®.
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30.

“Signatory Attorney General” shall mean the Attorney General o f Maine, or her

authorized designee, who has agreed to this Consent Judgment.
31.

“State Consumer Protection Laws” shall mean the consumer protection laws

under which the Attorneys General have conducted the investigation.12

32.

“Unsolicited Request” shall mean a request for information regarding Geodon®

from a non-Pfizer HCP communicated to an agent o f Pfizer that has not been prompted.

COMPLIANCE PROVISIONS

I.

Promotional Activities
A.

Pfizer shall not make any written or oral claim that is false, misleading or

deceptive regarding Geodon®.

1 ALABAMA - Alabama Deceptive Trade Practices Act, Ala. Code § 8-19-1 ot seq.; ARIZONA - A rizona C onsum er F raud A ct, A.R.S. 5 441521 el seq.; ARKANSAS - Arkansas Deceptive Trade Practices Act, Ark. Code Ann. § 4-88-101, e tse q ., CALIFORNIA - Bus. & ProfCode §§
17200 e l seq. and 17500 e l seq.; COLORADO - C olorado C onsum er P rotection A ct, Colo. Rev. Stat § 6-1-101 e l seq.; DELAWARE D elaw are C onsum er F raud A ct, Del. CODE ANN. lit. 6, §5 2511 to 2527; DISTRICT OF COLUMBIA, D istrict o f Colum bia Consum er
P rotection P rocedures A ct, D.C. Code §§ 28-3901 e t seq.; FLORIDA - F lorida D eceptive a n d U nfair Trade P ractices A ct, P art 11, Chapter 501,
Florida Statute», 501.201 et. seq.; HAWAII - U niform D eceptive T rade P ractice A ct, Haw. Rev. Stal. Chpt 48IA and Haw. 501.201 e t seq.;
IDAHO - C onsum er P rotection A ct, Idaho Code Section 48r601 e t seq. ; ILLINOIS - C onsum er F raud a n d D eceptive B usiness P ractices A d ,
815 ILCS 505/2 e l seq.; IOWA - Iow a C onsum er F raud A ct, Iowa Code Section 714.16; KANSAS - K ansas C onsum er P rotection A ct, K.SA.
50-623 et seq. KENTUCKY - K entucky C onsum er P rotection A ct, KRS Ch. 367.110, e t seq.; LOUISIANA - U nfair Trade-P ractices and
C onsum er P rotection Law , LSA-R S. 51:1401, e t seq.; MAINE - U nfair Trade P ractices A ct, 5 M.R.S.A. § 207 e t seq,; MARYLAND M aryland C onsum er P rotection A ct, Md. Code Ann., Com. Law §§ 13-10! e t seq.; MASSACHUSETTS - Mass. Gen. Laws c. 93A, §§ 2 and 4;
MICHIGAN - M ichigan C onsum er P rotection A ct. MCL § 445.901 */ seq.; MINNESOTA - Minnesota Deceptive Trade Practices Act, Minn.

Stat §§ 325D.43-48; Minnesota False Advertising Act, Minn. Stat § 325F.67; Minnesota Consumer Fraud Act, Minn. Stat §5 325F.68-70;
Minnesota Deceptive Trade Practices Against Senior Citizens or Disabled Persons Act Minn. Slat § 325F.71.; MISSOURI - M issouri
M erchandising P ra ctices A ct, Mo. Rev. Stat 55 407 cl seq.; MONTANA - Montana Code Annotated 30-14-101 e l seq .; NEBRASKA - Uniform
D eceptive Trade P ra ctices A ct, NRS §5 87-301 e t seq.; NEVADA - Deceptive Trade Practices Act Nevada Revised Statutes 598.0903 el seq.;
NEW JERSEY - N ew Jersey C onsum er F raud A d , NJSA 56:8-1 e l seq .; NEW MEXICO - NMSA 1978, 5 57-12-1 e l seq.; NEW YORK General Business Law Art 22-A, 5§ 349-50, and Executive Law 5 63(12); NORTH CAROLINA - North Carolina Unfair and Deceptive Trade
Practices Act N.C.G.S. 75-1.1, e t seq.; NORTH DAKOTA - U nlaw ful S a les or A dvertising P ractices, N.D. Cent Code § 51-15-02 e l seq.;
OHIO - O hio C onsum er Sa les P ractices A ct, R.C. 1345.01, e tse q .; OREGON - Oregon Unlawful Trade Practices Act Or. Rev. Slat. §646.605
el seq.; PENNSYLVANIA ■■P ennsylvania U nfair Trade P ractices a n d C onsum er P ro ted io n L aw , 73 P.S. 201-1 e tse q .; SOUTH CAROLINA South C arolina U nfair Trade P ractices A ct, sections 39-5-10 e t seq .; SOUTH DAKOTA' - S o u th D akota D eceptive Trade P ractices and
C onsum er P rotection, SDCL ch. 37-24; TENNESSEE - Tennessee C onsum er P rotection A d , Tenn. Code Ann. 47-18-101 e t seq.; TEXAS Texas D eceptive Trade P ractices C onsum er P rotection A ct, Tex. Bus, And Com. Code 17.47, e t seq.; VERMONT —C onsum er Fraud A d , 9
V.SA. §§ 2451 e t seq.; WASHINGTON - U nfair B usiness P rodices/C onsum er P rotection A d , RCW §§ 19.86 e l seq.; WEST VIRGINIA —
W est Virginia C onsum er C redit a n d P rotection A ct, W. Va. Code § 46A-1I01 e l seq.; WISCONSIN —Wis. Stat. § 100.18 (Fraudulent
Representations).
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B.

In Promotional Materials for Geodon®, Pfizer shall clearly and conspicuously

disclose the most serious risks associated with the product as set forth in the product’s labeling,
including information in any black box warning and shall present information about
effectiveness and information about risk in a balanced manner.
C.

Pfizer shall not Promote Geodon® for Off-Label uses.

D.

Pfizer shall not present patient profiles/types based on selected symptoms o f the

FDA-approved indication^) when Promoting Geodon®, unless:
1.

Geodon®’s specific FDA-approved indication(s) being Promoted'is/are

stated clearly and conspicuously on the same page or on a facing page in any physical Promotional
Materials that reference the selected symptoms;
a.

With respect to Promotional Slide Kits or computer tablet based
Promotional Materials:
(i)

Pfizer shall state clearly and conspicuously the FDAapproved indications) on the same slide in which selected
symptoms are first presented;

(ii)

Pfizer shall include a short-hand reference to the statement
described in Section I.D.l.a.(i) on the same slide as each
subsequent reference to selected symptoms (e.g., “See
complete list o f FDA-approved indications at p. X”); and
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b.

With respect to Promotional Slide Kits, Pfizer shall require any
presenter of Pfizer’s Promotional Slide Kits to present the
statements required in Section I.D.l.a.(i), as part of the mandatory
slides.

2.

Promotional

Materials have a reference indicating that the full

constellation o f symptoms and the relevant diagnostic criteria are available in the Diagnostic and
Statistical Manual o f Mental Disorders (DSM-IV or current version), where applicable.

E.

Pfizer shall ensure that all Promotional Speakers’ Promotional Materials for

Geodon® comply with Pfizer’s obligations in the above Sections IA . - D.
F.

Pfizer shall not award prizes or other incentives to its sales force as rewards for

the Off-Label sales or use o f Geodon®.

II.

Dissemination and Exchange o f Medical Information
A.

The content o f Pfizer’s communications concerning Off-Label uses o f Geodon®

shall not be false, misleading or deceptive.

B.

Medical Information Letters
1.

The following subsections shall be effective for nine years from the

Effective Date o f this Consent Judgment.
2.

Pfizer Medical shall have ultimate responsibility for developing and

approving the medical content for all Medical Information Letters regarding Geodon®, including
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any that may describe Off-Label information. Additional approvals may be provided by Pfizer’s
legal department. Pfizer shall not distribute any such materials unless:
a.

Clinically Relevant Information is included in these materials to
provide scientific balance;

b.

Data in these materials are presented in an unbiased, nonPromotional manner; and

c.

These materials are clearly distinguishable from sales aids and
other Promotional Materials.

3.

Pfizer Sales and Pfizer Marketing personnel shall not develop the medical

content o f Medical Information Letters regarding Geodon®. This provision does not prohibit
Pfizer Sales or Pfizer Marketing personnel from suggesting topics for Medical Information
Letters.
4.

Pfizer Sales and Pfizer Marketing personnel shall not distribute Medical

Reference Publications or Medical Information Letters regarding Geodon®.

5.

Pfizer shall not knowingly disseminate any Medical Information Letter

describing any Off-Label use o f Geodoii® that makes any false, misleading or deceptive
representation regarding Geodon® or any false, misleading or deceptive statement concerning a
competing product.

C.

Responses to Unsolicited Requests for Off-Label Information
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1.

The following subsections shall be effective for nine years from the

Effective Date o f this Consent Judgment.
2.

In responding to an Unsolicited Request for Off-Label information

regarding Geodon®, including any request for a specific article related to Off-Label uses, Pfizer
shall advise the requestor that the request concerns an Off-Label use and inform the requestor of
the drug’s FDA-approved indications) and/or dosage and other relevant Labeling information,

3.

If Pfizer elects to respond to an Unsolicited Request for Off-Label

information from a HCP regarding Geodon®, Pfizer Medical personnel shall provide specific,
accurate, objective, and scientifically balanced responses. Any such response shall not Promote
Geodon® for any Off-Label use(s).

4.

Any written response to an Unsolicited Request for Off-Label information

regarding Geodon® shall include:
a.

an existing Medical Information Letter prepared in accordance
with Section II.B;

b.

a Medical Information Letter or other document prepared in
response to the request in accordance with Section II.B; or

c.

a report containing the results of a reasonable literature search
using terms from the request.

5.

Pfizer Sales and Pfizer Marketing personnel may respond in writing to an

Unsolicited Request for Off-Label information regarding Geodon® from an HCP only by
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informing the HCP o f the presence or absence o f published studies concerning the Off-Label
topic or by acknowledging whether the topic is an area o f research, and by offering to request on
behalf o f the HCP that a Medical Information Letter or other information be sent to the HCP in
follow up, provided it complies with suh-Section II.C.4 set forth above. Pfizer Sales and Pfizer
Marketing personnel shall not characterize, describe, identify, name, or offer any opinions about
or summarize any such Off-Label information.

Notwithstanding the foregoing, Medical

Outcomes Specialists may discuss in writing issues relating to pharmacoeconomics or health
outcomes with third party payors, including but not limited to managed care organizations and
employers responsible for the . administration o f health benefits, but hot prescribes unless
employed or engaged by payors in a non-prescribing role.

6.

Pfizer Sales and Pfizer Marketing personnel may respond orally to an

Unsolicited Request for Off-Label information regarding Geodon© from an HCP only by
informing the HCP o f the presence or absence o f published studies concerning the Off-Label
topic or by acknowledging whether the topic is an area o f research, and by offering to request on
behalf o f the HCP that a Medical Information Letter or other information be sent to the HCP in
follow up, provided it complies with sub-Section II.C.4 set forth above. Pfizer Sales and Pfizer
Marketing personnel shall not characterize, describe, identify, name, or offer any opinions about
or summarize any such Off-Label information.

Notwithstanding the foregoing, Medical

Outcomes Specialists may discuss orally issues relating to pharmacoeconomics or health
outcomes with third party payors, including but not limited to managed care organizations and
employers responsible for the administration o f health benefits, but not prescribes unless
employed or engaged by payors in a non-prescribing role.
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D.

Reprints
1.

Pfizer shall not disseminate any information describing any Off-Label use

o f Geodon® if such use has been submitted to the FDA for approval and the FDA has either
advised Pfizer that it refuses to approve such application or that FDA*identified deficiencies
must be resolved before approval can be granted unless Pfizer has first clearly and conspicuously
disclosed to the recipient o f the information that the FDA had issued such advice regarding such
Off-Label use. Pfizer may disclose to any recipient o f such information whether the information
was presented to the FDA prior to the FDA’s issuance o f such advice regarding the Off-Label
use.
2.

Pfizer shall not disseminate a Medical Information Letter, an unabridged

reprint or copy o f an article from a peer reviewed journal or a Reference Publication, or
written information through a Regional Medical Research Specialist (“RMRS” )
describing any Off-Label use of Geodon® in response to an Unsolicited Request unless:
a.

the information is about a clinical investigation with respect to
Geodon® and experts qualified by scientific training or experience
to evaluate the safety or effectiveness o f Geodon® would consider
the subject o f the clinical investigation to be scientifically sound or
the information is an unabridged reprint or copy o f an article from
a peer reviewed journal or a Reference Publication;
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b.

the information is accompanied by a comprehensive bibliography
o f publications discussing adequate and well-controlled clinical
studies published in a medical journal or medical or scientific text
that have been previously published about the use o f Geodon®
covered by the information (unless the information is a peer
reviewed journal or Reference Publication which already includes
such a bibliography); and

c.

in cases in which experts qualified by scientific training or
experience to evaluate the safety or effectiveness o f Geodon®
would consider the conclusion o f the information to have been
specifically called into question by another article(s) or text(s) that
experts qualified by scientific training or experience to evaluate the
safety or effectiveness o f Geodon® would consider to be
scientifically sound, the information must be disseminated with a
representative publication that reaches contrary or different
conclusions regarding the Off-Label use.

3.

Reprints Containing Off-Label Information
a.

Pfizer Medical shall be responsible for the identification, selection,
approval and dissemination of Reprints Containing Off-Label
Information regarding Geodon®.

b.

Reprints Containing Off-Label Information regarding Geodon®:
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(i) shall be accompanied by the full prescribing information
for the product and contain a disclosure in a prominent
location, which would include the first page or as a cover
page where practicable, indicating that the article may
discuss Off-Label information; and
(ii) shall not be referred to or used in a Promotional manner.
c.

Reprints Containing Off-Label Information regarding Geodon®
may only be disseminated by Pfizer Medical personnel to HCPs.
Pfizer Sales or Pfizer Marketing personnel shall not disseminate
these materials to HCPs, absent the exception described below in
(i); provided, however, that Medical Outcomes Specialists may
disseminate reprints relating to pharmacoeconomics or health
outcomes to third party payors, including but not limited to
managed care organizations and employers responsible for the
administration o f health benefits, but not prescribes unless
employed or engaged by payors in a non-prescribing role.
(i)

In the event o f an extraordinary circumstance in which
there is a clinical necessity to have Pfizer Sales or Pfizer
Marketing personnel disseminate a Reprint Containing OffLabel information directly to HCPs, the President o f Pfizer
Worldwide Pharmaceutical Operations may approve a
Clinical Necessity Exception to the prohibition described in
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Section H.D.3.C above for that Reprint Containing OffLabel information.
(ii) If the Clinical Necessity Exception is invoked, Pfizer will
notify each Signatory Attorney General of its intent to
invoke the Clinical Necessity Exception at least 30 business
days

prior

to

representatives

disseminating
any

Reprint

through. Pfizer
Containing

sales

Off-Label

information on Geodon®.
(a) If a Signatory Attorney General believes the Reprint
Containing Off-Label information to be disseminated

does not meet the Clinical Necessity Exception, then
the State will provide Pfizer with written notice within
30 business days and provide Pfizer an opportunity to
discuss its desired use o f the Reprint Containing OffLabel information pursuant to the limited exception.
(b) If the State and Pfizer do not come to a resolution, then
the State may initiate legal action to prevent the
dissemination o f the Reprint Containing Off-Label
information by Pfizer Sales or Pfizer Marketing
personnel.
(c) I f the State initiates legal action to prevent the
dissemination o f the Reprint Containing Off-Label
information by Pfizer Sales or Pfizer Marketing
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personnel, Pfizer shall not use Pfizer Sales or Pfizer
Marketing personnel to disseminate such Reprint
Containing Off-Label information in that State until the
issue has been resolved.
4.

Nothing

in

this

Consent

Judgment shall

preclude Pfizer

from

disseminating Reprints Containing Off-Label information which have an incidental reference to
Off-Label information. If reprints have an incidental reference to Off-Label information, such
reprints shall contain the disclosure required by Section II.D.3.b(i) in a prominent location, as
defined above.
5.

Pfizer shall not disseminate any reprint or copy o f an article from a peer

reviewed journal or a Medical Reference Publication describing any Off-Label use o f Geodon®
to physician specialties that do not customarily prescribe Geodon® if these materials combined
with detailing, advertising, sampling, or other Promotional activities Promote Off-Label use of
Geodon®.
6.

In disseminating information about Off-label usage, Pfizer shall either

follow the substantive procedures in Section IV o f the January, 2009, FDA guidance entitled
Good Reprint Practices for the Distribution o f Medical Journal Articles and Medical or Scientific
Reference Publications on Unapproved New Uses o f Approved Drugs and Approved or Cleared
Medical Devices or use an alternative approach provided such approach satisfies the
requirements o f the applicable statutes and regulations.
E.

Pfizer shall develop, implement and maintain policies and procedures to ensure

that Medical Science Liaisons do not promote Off-label uses of Geodon® and to ensure that they
do not engage in the improper marketing o f Geodon®.
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III.

Continuing Medical Education (CME1 and Grants

A.

The following subsections shall be effective for six years from the Effective Date

o f this Consent Judgment.
B.

Pfizer shall disclose information about grants, including CME grants, regarding

Geodon® consistent with the current disclosures o f the Pfizer Medical Education Grants Office
registry at http://www.pfizer.com/resDonsibilitv/grants payments/medical education gTants.isp
(hereinafter, “Pfizer Medical Education Grants Office website”) or as required by applicable law.
1.

Once posted, Pfizer shall maintain this information on the Pfizer Medical

Education Grants Office website for at least two years and shall maintain the information in a
readily accessible format for review by the States upon written request for a period of five years.
C.

The Pfizer Medical Education Grants Office shall manage all requests for funding

related to ÇME relating to Geodon®. Approval decisions shall be made by the Pfizer Medical
Education Grants Office and Pfizer Medical, and shall be kept separate from thè Pfizer Sales and
Pfizer Marketing organizations.
D.

Pfizer shall not use grants to Promote Geodon®. This provision includes, but is

not limited to, the following prohibitions:
1.

Pfizer Sales and Pfizer Marketing personnel shall not initiate, coordinate

or implement grant applications on behalf of any customer or HCP;.
2.

Pfizer Sales and Pfizer Marketing personnel shall not be involved in

selecting grantees or CME-fiinded speakers; and
3.

Pfizer Sales and Pfizer Marketing personnel shall not measure or attempt

to track in any way the impact o f grants or speaking fees on the participating HCPs’ subsequent
prescribing habits, practices or patterns.
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E.

Pfizer shall not condition funding of a CME program grant request relating to

Geodon® upon the requestor’s selection or rejection o f particular speakers.
F.

Pfizer shall not suggest, control, or attempt to influence selection o f the specific

topic, title, content, speakers or audience for CMEs relating to Geodon®, consistent with
ACCME guidelines.
G.

Pfizer Sales and Pfizer Marketing personnel shall not approve grant requests

regarding Geodon®, nor attempt to influence the Pfizer Medical Education Grants Office to
reward any customers or HCPs with grants for their prescribing habits, practices or patterns.
H.

Pfizer shall contractually require the CME provider to disclose to CME program

attendees Pfizer’s financial support o f the CME program and any financial relationship with
faculty and speakers at such CME.
I.

After the initial delivery o f a CME program, Pfizer shall not fund the same

program, nor shall it provide additional funding for re-distribution o f the same program, if Pfizer
Medical Education Grants Office or Pfizer Medical knows that the program’s speakers are
Promoting Geodon® for Off-Label uses, unless it takes specific action that ensures that such
Promotion does not occur.
IV.

Payments to Speakers and HCPs
A.

On or before March 31, 2011, Pfizer shall post in a prominent position on its

website an easily accessible and readily searchable listing o f all U.S.-based physicians, and
Related Entities who or which received Payments directly or indirectly from Pfizer between July
1,2010 and December 31,2010 and the aggregate value o f such Payments.
B.

After the initial posting, Pfizer shall post annual listings on March 31, 2012 and

March 31 o f each of the three successive years. The annual listing on March 31, 2012 and
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thereafter shall include cumulative information about Payments made by Pfizer during each o f
the respective prior calendar years.
C.

In addition, beginning on June 1, 2012, Pfizer shall include on its website a listing

o f all U.S. based physicians and Related Entities who or which received Payments from Pfizer
during the first calendar quarter o f 2012. Thereafter, 60 days after the end o f each subsequent
calendar quarter, Pfizer shall also post on its website a listing of updated information about all
Payments provided during the preceding quarter(s) in each calendar year. The quarterly and
annual reports shall be easily accessible and readily searchable.
D.

Each listing made pursuant to this section shall include a complete list of all

individual physicians, and/or Related Entities to whom or to which Pfizer directly or indirectly
made Payments in the preceding calendar year for 2011 and after June 1,2012 for the preceding
quarter or year (as applicable). Each listing shall be arranged alphabetically according to the
physicians' last name or the name o f the Related Entity. The Payment amounts in the lists shall
be reported in $10,000 increments (e.g., $0 - $10,000; $10,001- $20,000; etc.) or in the actual
amount paid, provided, however, that the Payment amounts shall be listed in the same way
(incrementally or in actual amounts) for all physicians and/or Related Entities on the listing. For
each physician, the applicable listing shall include the following information: i) physician’s full
name; ii) name ,of any Related Entities (if applicable); iii) city and state that the physician or
Related Entity has provided to Pfizer for contact purposes; and (iv) the aggregate value o f the
Payments) in the preceding quarters) or year (as applicable).

I f Payments for multiple

physicians have been made to one Related Entity, the aggregate value o f all Payments to the
Related Entity will be the reported amount.
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E.

Pfizer shall continue to make each annual listing and the most recent quarterly

listing o f Payments available on its website at least through March 31, 2014. Pfizer shall retain
and make available to the State, upon request, all work papers, supporting documentation,
correspondence, and records related to all applicable Payments and to the annual and quarterly
listings o f Payments. Nothing in this section affects the responsibility o f Pfizer to comply with
(or liability for noncompliance with) all applicable Federal health care program requirements and
state laws as they relate to all applicable Payments made to physicians or Related Entities.
F.

If the proposed Physician Payments Sunshine Act o f 2009 or similar legislation is

enacted, the State shall détermine whether the purposes o f this section are reasonably satisfied by
Pfizer’s compliance with such legislation. In such case, and in its sole discretion, the State may
/

agree to modify or terminate provisions o f this section as appropriate.
G.

The term “physician” as used in this section does not include bona-fide employees

o f Pfizer or its subsidiaries.
H.

Pfizer’s posting o f Payment information shall be subject to any applicable

confidentiality provisions contained in clinical research agreements that were entered with a
U. S.-based physician prior to July 1, 2009. Pfizer agrees that it shall not include any such
confidentiality provisions in any new or renewed clinical research agreements entered after the
Effective Date o f this Consent Judgment that require any Payment to a U.S.-based physician.
V.

Product Samples

A.

The following subsections shall be effective for nine years from the Effective

Date o f this Consent Judgment.
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B.

Pfizer shall only provide samples of Geodon® to those HCPs who have

specialties that customarily treat patients who have diseases for which treatment with Geodon®
would be consistent with Geodon®’s Labeling.
C.

If a HCP whose clinical practice is inconsistent with the product’s Labeling

requests samples, Pfizer personnel shall refer the practitioner to 1-800-438-1985 where the
practitioner can speak directly with a Pfizer representative who will provide answers to the
HCP’s questions about Geodon® and may provide them with samples only if appropriate (i.e., if
the physician requests the sample for an on-label use).
D.

Pfizer shall not disseminate samples o f Geodon® with the intent of increasing

Off-Label prescribing o f Geodon®.
VI.

Clinical Research
A.

Pfizer shall report research regarding Geodon® in an accurate, objective and

balanced manner as follows and as required by applicable law:
1.

To the extent permitted by the National Library o f Medicine and as

required by the FDA Amendments Act (Public Law No. 110-85), Pfizer shall register clinical
trials and submit results to the registry and results data bank regarding Geodon® as required by
the FDA Amendments Act and any accompanying regulations that may be promulgated pursuant
to that Act. With respect to Geodon®, Pfizer shalj register on a publicly accessible website all
Pfizer-sponsored Phase II, III and IV clinical trials, to the extent available, that were ongoing or
initiated after July 1, 2005 and will post results on a publicly accessible website o f all Pfizersponsored Phase II, III and IV clinical trials, to the extent available, that were completed after
October 2002.
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B.

When presenting information about a clinical study regarding Geodon® in any

Promotional Materials, Pfizer shall not do any o f the following:
1.

present favorable information or conclusions from a . study that is

inadequate in design, scope, or conduct to furnish significant support for such information or
conclusions;
2.

use the concept o f statistical significance to support a claim that has not

been demonstrated to have clinical significance or validity, or fails to reveal the range of
variations around the quoted average results;
. 3.

use statistical analyses and techniques on a retrospective basis to discover

and cite findings not soundly supported by the study, or to suggest scientific validity and rigor
for data from studies the design or protocol o f which are not amenable to formal statistical
evaluations;
4.

present the information in a way that implies that the study represents

larger or more general experience with the drug than it actually does; or
5.

use statistics on numbers o f patients, or counts o f favorable results or side

effects, derived from pooling data from various insignificant or dissimilar studies in a way that
suggests either that such statistics are valid if they are not or that they are derived from large or
significant studies supporting favorable conclusions when such is not the case.
VII.

Terms Relating to Payment
A.

No later than 30 days after the Effective Date of this Order, Pfizer shall pay a total

amount o f $33 million to be divided and paid by Pfizer directly to each Signatory Attorney
General o f the Multistate Working Group in an amount to be designated by and in the sole
discretion o f the Multistate Executive Committee. Said payment shall be used by the States as
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and for attorneys’ fees and other costs o f investigation and litigation, or to be placed in, or
applied to, the consumer protection enforcement fund, including future consumer protection
enforcement, consumer education, litigation or local consumer aid fund or revolving fund, used
to defray the costs o f the inquiry leading hereto, and may be used to fund or assist in funding
programs directed at mental illness treatment, including but not limited to education and outreach
or for other uses permitted by state law, at the sole discretion of each Signatory Attorney
General The Parties acknowledge that the payment described herein is not a fine penalty, or
payment in lieu thereof

VIII.

Release
A.

By its execution o f this Consent Judgment, the State o f Maine releases Pfizer and

all o f its past and present subsidiaries, affiliates, predecessors and successors (collectively, the
“Released Parties”) from the following: all civil claims, causes of action, damages, restitution,
fines, costs, and penalties that the Maine Attorney General could have asserted against the
Released Parties under the above-cited consumer protection statutes resulting from the Covered
Conduct up to and including the Effective Date that is the subject o f this Consent Judgment.
B.

Notwithstanding any term o f this Consent Judgment, specifically reserved and

excluded from the Release in Paragraph VHI.A. as to any entity or person, including Released
Parties, are any and all o f the following:
1.

Any criminal liability that any person and/or entity, including Released

Parties, has or may have to the State o f Maine.
2;

Any civil or administrative liability that any person and/or entity,

including Released Parties, has or may have to the State o f Maine not expressly covered by the
release in Paragraph (A) above, including but not limited to any and all o f the following claims:
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a)

State or federal antitrust violations;

b)

Reporting practices, including “best price”, “average wholesale
price” or “wholesale acquisition cost,*”

c)

Medicaid violations, including federal Medicaid drug rebate statute
violations, Medicaid fraud or abuse, and/or kickback violations
related to any State’s Medicaid program; and,

d)
3.

State false claims violations.

Any liability under the State o f Maine’s above-cited consumer protection

laws which any person and/or entity, including Released Parties, has or may have to individual
consumers or State program payors o f said State.
4.

Any liability for failure to comply with Maine’s Prescription Drug Clinical

Trial Reporting Rule: DHS Rule 10-144 Ch. 275, AG Rule 26-0259 Ch. 11 with respect to any
drug other than Geodon.
IX

Nothing contained in this Judgment Order shall relieve or release Pfizer o f the obligations

it maintains under any other Consent Judgment or agreement relating to any Pfizer product.
X.

Dispute Resolution
A.

For the purposes o f resolving disputes with respect to compliance with this

Consent Judgment, should any o f the Signatory Attorneys General have a reasonable basis to
believe that Pfizer has engaged in a practice that violates a provision o f this Consent Judgment
subsequent to the Effective Date o f this Judgment, then such Attorney General shall notify Pfizer
in writing o f the specific objection, identify with particularity the provisions of this Consent
Judgment that the practice appears to violate, and give Pfizer thirty (30) days to respond to the
notification; provided, however, that a Signatory Attorney General may take any action if the
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Signatory Attorney General concludes that, because of the specific practice, a threat to the health
or safety o f the public requires immediate action. Upon receipt o f written notice, Pfizer shall
provide a good-faith written response to the Attorney General notification, containing either a
statement explaining why Pfizer believes it is in compliance with the Consent Judgment, or a
detailed explanation o f how the alleged violation occurred and a statement explaining how Pfizer
intends to remedy the alleged breach. Nothing in this paragraph shall be interpreted to limit the
state’s Civil Investigative Demand (“CID”) or investigative subpoena authority, to the extent
such authority exists under applicable state law, and Pfizer reserves all of its rights with respect
to a CID or investigative subpoena issued pursuant to such authority.
B.

Upon giving Pfizer thirty (30) days to respond to the notification described above,

the Signatory Attorney General shall also be permitted reasonable access to inspect and copy
relevant, non-privileged, non-work product records and documents in the possession, custody or
control o f Pfizer that relate to Pfizer’s compliance with each provision o f this Consent Judgment
as to which cause that is legally sufficient in the State has been shown. I f the Signatory Attorney
General makes or requests copies of any documents during the course of that inspection, the
Signatory Attorney General will provide a list o f those documents to Pfizer.
C.

The State may assert any claim that Pfizer has violated this Consent Judgment in a

separate civil action to enforce compliance with this Consent Judgment, or may seek any other
relief afforded by law, but only after providing Pfizer an opportunity to respond to the
notification described in Paragraph X.A. above; provided, however, that a Signatory Attorney
General may take any action if the Signatory Attorney General concludes that, because o f the
specific practice, a threat to the health or safety o f the public requires immediate action.
XI.

General Provisions
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A.

This Consent Judgment represents the full and complete terms o f the settlement

entered into by the Parties hereto. In any action undertaken by the Parties, no prior versions o f
this Consent Judgment and no prior versions o f any o f its terms that were not entered by the
Court in this Consent Judgment, may be introduced for any purpose whatsoever.
B.

This Court retains jurisdiction o f this Consent Judgment and the Parties hereto for

the purpose o f enforcing and modifying this Consent Judgment and for the purpose o f granting
such add itional relief as may be necessary and appropriate.
C.

This Consent Judgment may be executed in counterparts, and a facsimile or PDF

signature shall be deemed to be, and shall have the same force and effect as, an original
signature.
D.

All Notices under this Order shall be provided to the following via Overnight

Mail:
For the State o f Maine:

Chief Consumer Protection Division
Office o f the Maine Attorney General
6 State House Station
Augusta, ME 04333-0006

For Pfizer Inc.:

Douglas M. Lankier
Senior Vice President
And Chief Compliance Officer
Pfizer Inc.
150 East 42nd Street
New York, New York 10017

E.

To the extent that any provision o f this Consent Judgment obligates Pfizer to

change any policy(ies) or procedure(s) and to the extent not already accomplished, Pfizer shall
implement the policy(ies) or procedure(s) as soon as reasonably practicable, but no. later than 120
days after the Effective Date o f this Consent Judgment.
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IT IS HEREBY ORDERED, ADJUDGED AND DECREED.

Dated:

For Plaintiff:

JANET T. MILLS
ATTORNEY GENERAL

Dated: S eptem ber^, 2009
CAROLYN & SILSBY, Bar No. 3030^
ASSISTANT ATTORNEY GENERAT
Office o f the Maine Attorney General
6 State House Station
Augusta, ME 04333-0006
(207)626-8829
Carolyn.silsby@maine.gov
ATTORNEYS FOR THE STATE OF MAINE
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For Defendant:

Dated: September 2. , 2009
RUSSELL B. PIERCE, JR., Bar No.
Norman, Hanson & DeTroy, LLC
415 Congress Street
P.O. Box 4600
Portland, ME 04112-4600
(207) 774 7000
ATTORNEY FOR PFIZER INC.

31

For Pfizer Inc.:

Douglas M. Lankier
Senior Vice President
And Chief Compliance Officer
Pfizer Inc.
Date:

Bnen T. O’Connor

Ropes & Gray
One International Place
Boston,MA 021)0
Date:

^

J | 0^
I

By: j.
Í
DLA Piper LLP (US)
33 Arch Street, 26th Floor
Boston, MA 02110
Date:

____________

OÁj&prgJL
stofajou& ter-

AM

vn

\

For Pfizer Inc*:

Douglas M. Lankier
Senior Vice President
And C hief Compliance O fficer
Pfizer Inc.
Date:_________________________

B y :___ L Ll—\ ] * ^
----- :
Brien T. O ’Connor
Ropes & Gray LLP
One International Place
Boston, M A 02110
Date:

DLA Piper LLP (US)
33 Arch Street, 26th Floor
Boston, MA 02110
Date:

ri.
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This summary sheet and the intbimation contained herein neither replace nor supplement the tiling and service oi pleadings or other papers as
required by the Maine Rules of Court or by law. This form is required for the use of the Clerk of Court for the-purpose of initiating or
updating the civil docket. (SEE INSTRUCTIONS ON REVERSE)________________________________________________________
I. County of Filing or District Court Jurisdiction: Kennebec
II. CAUSE OF ACTION (Cite the primary civil statutes under which you are filing, ifany.)

P ro s e

plaintiffs: I f unsure, leave blank.

Unfair Trade Practices Act, 5 M.R.S.A. §207

III.

NATURE OF FILING
m Initial Complaint
I I Third-Party Complaint
□ Cross-Claim or Counterclaim
I~1 If Reinstated or Reopened case, give original Docket Num ber_________________________________ ■_

(If filing a second or subsequent Money Judgment Disclosure, give docket number of first disclosure)
IV.
V.

•
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□
□
□
□
□
□
□
□
□
□
□

□

TITLE TO REAL ESTATE IS INVOLVED

MOST DEFINITIVE NATURE OF ACTION. (Place anX in one box only )

P ro s e

GENERAL CIVIL fCVl
C ontract
□
1 1 Contract
□
D eclaratory/E quitable Relief
□
] General Injunctive Relief
□
] Declaratory Judgment
□
] Other Equitable Relief
□
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□
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□
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□
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□
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Freedom of Access
□
1 1 Other Statutory Actions
u
M iscellaneous Civil
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1 1 Drug Forfeitures
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Auto Negligence
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Product Liability
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Other Negligence
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Non-Personal In ju ry T ort
Libel/Defamation
Auto Negligence
Other Negligence
Other Non-Personal Injury Tort

n

plaintiffs: If u n su re, leave blank.

Other Forfeitures/Properiy Libels
Land Use Enforcement (80K)
Administrative Warrant
HIV Testing .
Arbitration Awards
Appointment of Receiver
Shareholders' Derivative Actions
Foreign Deposition
Pre-action Discovery
Common Law Habeas Corpus
Prisoner Transfers
Foreign Judgments
Minor Settlements
Other Civil

F I Non-DHS Protective Custody
SPECIAL ACTIONS <SA1
L

Money Judgm ent
Money Judgmenl Requcs t Disclosure

1 1
1 1
F~1
(]

T itle A ctions
Quiet Title
Eminent Domain
Easements
Boundaries

□

Governmental Body (80B)

VI.

REAL ESTATE (RE1
Mise. Real Estate
Foreclosure
1 1 Equitable Remedies l~l Nuisance
Foreclosure
for
Non-pmt
(ADR
exempt)
□
I l Abandoned Roads
1 1 Mechanics Lien
□ Foreclosure - Other
1 1 Other Real Estate
1 1 Partition
Trespass
1
1 Adverse Possession
□ Trespass
APPEALS IAP) ITo be filed in Superior Courtl (ADR exempt)
□ Administrative Agency (80C)
Q Other Appeals

M .R.Civ.P. 16B A lternative Dispute Resolution (ADR):
f~l I certify that pursuant to M.R.Civ.P. 16B(b), this case is exempt from a required ADR process because:
□ It falls within an exemption listed above (i.e., an appeal or an action for non-payment of a note in a secured transaction).
□ The plaintiff or defendant is incarcerated in a local, state or federal facility.
□ The parties have participated in a statutory prelitigation screening process with__________ :________________ ■
(name of neutral) on ______________________________ (date).
□ The parties have participated in a formal ADR process with __________________________________ (name of neutral)
on________________________________(date).
□ This is a Personal Injury action in which the plaintiff’s likely damages will not exceed $30,000, and ihe plaintiff requests an
__________ exemption from ADR._____________ ________ _______________________________________________________

rV -001. Rev. 01/0?

| VII. (a)(2) PLAINTIFFS (Name & Address including county)
or □ T hird-P arty, Q Counterclaim or Cross-Claim P laintiffs
f~~) The plaintiff is a prisoner in a local, state or federal facility.
State of Maine

(b) Attorneys (Name, Bar number, Firm name, Address, Telephone Number) I f al) counsel listed do NOT rep resen t ail plaintiffs,
( I f p r o s e p la in tiff, leave blank)
specify who the listed attorney(s) rep resen t.
Carolyn A. Silsby, Bar No. 3030
Assistant Attorney General
Office of the Attorney General
State House Station
Augusta, Maine 04333-0006
207-626-8829

VIII. ( a ) ^ DEFENDANTS (Name & Address including county)
and/or i~l T hird-P arty. I I Counterclaim or t~l Cross-Claim D efendants
I I The defendant is a prisoner in a local, state or federal facility.
Pfizer, Inc.

(b) Attorneys (Name, Bar number, Firm name, Address, Telephone Number)
(If known)
Russell B. Pierce, Jr., Esq. Bar No. 7322
Norman Hanson & DeTroy, LLC
415 Congress Street
P.O . Box 4600
Portland, Maine 04112

IX.

RELATED CASE(S) IF ANY______________________________________
Assigned Judge/Iustice_________________________

Date: Septem bers. 2009

Docket Number

Carolyn A. Silsby, Assistant Attorney General

Nam'
Signature
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If all counsel listed do NOT rep resen t all
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Pro se Party
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STATE OF MAINE
SUPERIOR COURT
KENNEBEC______________ , ss.
Docket No. CV-Q9-________

DISTRICT COURT
Location_________
Docket N o._______

STATE OF MAINE_____________
Plaintiff
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APPLICATION FOR TRANSFER TO
BUSINESS AND CONSUMER DOCKET

PFIZER, INC.______________
Defendant

I/We submit this application for transfer of the above-captioned case to the BCD, based on the following information:
Plaintiff

NAME OF EACH PARTY SUBMITTING THIS APPLICATION:

STATE OF MAINE

Defendant
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□
□

1. Is at least One party a business entity?

13 Yes

□

CD No

2. List all plaintiffs and their counsel:
COUNSEL (NAME AND ADDRESS)

PIAINTII'im

STATE OF MAINE

EMAIL ADDRESS

CAROLYN A. SILSBY
carolyn.silsby@maine.gov
Bar No. 3030
Assistant Attorney General
6 State House Station
-Angusta» H E _04333=0005____

3. List all defendants and their counsel:
COUNSEL (NAMEAND ADDRESS)

DEFENDANTS')

PFIZER, INC.

4 . List

E-MAIL ADDRESS

RUSSELL B. PIERCE, JR., ESQ roierce@nhdlaw.com
Bar No. 7322
1
Norman. Hanson & DeTrov. LL(
415 Congress Street
P...0__Boy 4500. Por.t.1.anri, MF,
04112

any other cases with which this case is or may need be consolidated or coordinated:
DOCKET NUMBER

CASE CAPTION
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CURRENT COURT LOCATION

5. What is the subject matter of the primary cause of action in this case:
□

n
□
□
O
□

□
□
i]
1]
11
I I
0
H

Breach o f Contract
Breach of Fiduciary Duty
80B Appeal involving a business entity
Internal governance of a business entity
Shareholder derivative action
Intellectual property
U.C.C. transactions
Antitrust or other trade regulations
Other (describe): __________________

Breach of Warranty
Class Action
80C Appeal involving a business entity
Securities transactions
Confidential or trade secret
Financial transactions
Unfair trade practices
Commercial real estate

NOT YET
DETERMINED

6. What is the status of this case:
YES
a. Has service of the complaint been completed on all
parties?........................................................................
b. Are the pleadings closed? ....... ..................................
c. Is discovery completed?........................................... .
d. Is class action status sought?.......................................
e. Scheduled for trial? If so, w hen?................................
f. Pretrial held?...........................................................
g Case management conference held? .........................
h. Jury trial? ......... .......... .......................... ............ .
■i. B e n c h f r i a l ? ....... .................. .......
j . ADR been attempted?................ ................................
k. Is file sealed (partial / entire)?.................................... .
l. Will post-judgment judicial supervision be needed? ...

m. Consent Judgment Filed

NO

□
□
□
□
□

□
□
□
□
□
□
□
□

□
□
□
□
□
□
□
□
□
□
□

□ *■

□

□
□

□
□
□

X

□
□

•

7. What is the estimated length o f trial (in days)? __________
8. Identify nature and number of any pending pretrial motions:

9. Identify anv novel and/or comnlèx lésai issues in this case:

10. Do ail of the parties appearing in the case agree to a transfer?

□

(X] YES

•

NO

CERTIFICATION OF SERVICE BY ATTORNEY OR PARIW SI 1OMITTING APPLICATION
I hereby certify thdfci copy was mailed/delivered to ail cdrmse} and pro se parlies of record on Ihis date
SIGNED:

( L
0

DATE

.

_
V ________________________
ORDER (For B$b Court Use Only)
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The above Application having been considered, it is ORDERED as follows:
□
□

The case is ACCEPTED for transfer. The case file shall be transferred forthwith from the court in which the case is now
pending to the BCD.
The case is NOT ACCEPTED for transfer.
DATE

SIGNED (BCD Justice/Judge)
PLEASE NOTE THE FOLLOWING:

A. Failure to supply complete and accurate information may disqualify a case for consideration for transfer to
the BCD.
B. Information that does not fit on this form should be attached to a separate sheet and numbered to correspond
to the inquiries on the form.
C. This application should be filed with the court in which the case is currently pending.
BCD-001
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SUPERIOR COURT
CIVIL ACTION
DOCKET NO. CV-09-

STATE OF MAINE
KENNEBEC, SS

STATE OF MAINE,
Plaintiff,
V.

PFIZER INC.,
Defendant

)
)
)
)
)
)
)
)

COMPLAINT
(Includes Request for
Injunctive Relief)

INTRODUCTION
1.

Plaintiff, the State o f Maine, brings this action, by and through its Attorney

General, complaining of Defendant PFIZER, INC., a Delaware corporation, for violating 5
M.R.S.A. § 207 o f the Maine Unfair Trade Practices Act (“UTPA”) as follows:
PARTIES
2.

Plaintiff, the State o f Maine, brings this action by and through its Attorney

General, Janet T. Mills, in the public interest pursuant to the authority granted her under 5
M.R.S.A. § 209.
3.

Defendant Pfizer, Inc., (“Pfizer” or “Defendant”), is a Delaware corporation with

its principal place of business in New York. Pfizer transacts business in the State o f Maine by
advertising, soliciting, selling, promoting and distributing prescription drugs, including
Geodon®, to consumers in the State o f Maine and nationwide.

JU RISD ICTIO N A ND V EN U E

4.

This Court has jurisdiction over the subject matter o f this action pursuant to 5

M.R.S.A. § 209 and 4 M.R.S.A. § 105. Venue is proper in this Court pursuant to 5 M.R.S.A.
§209.
BACKGROUND
5.

Geodon belongs to a class o f drugs traditionally used to treat schizophrenia and

commonly referred to as “atypical antipsychotics.” When these drugs were first introduced to
the market in the 1990s, it was hypothesized that they might be used as long-term treatment for
schizophrenia without posing the same risks as first-generation antipsychotics.
6.

While these drugs may reduce some risks associated with first-generation

antipsychotics, they also produce dangerous side effects, including weight gain, hyperglycemia,
diabetes, cardiovascular complications, and other severe conditions.
7.

Geodon was first approved by the Food and Drug Administration (“FDA”) for the

treatment of schizophrenia in February, 2001. Since then, the FDA has approved various
formulations of Geodon for the treatment of acute agitation in schizophrenic patients requiring
rapid treatment, the treatment o f acute manic or mixed episodes in Bipolar I Disorder, and/or the
treatment o f both schizophrenia and bipolar disorder.
DEFENDANT’S COURSE OF CONDUCT
8.

Pfizer not only began to market Geodon to health care professionals for the

treatment o f schizophrenia in 2001, it also marketed Geodon for a number of uses for which it
was not approved by the FDA. For example, Pfizer illegally promoted Geodon for a variety of
off-label purposes including, but not limited to, for use in pediatric patients and for use in higher
than FDA-approved dosages.
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9.

Through all o f the company’s efforts to promote Geodon for uses that were not

approved by the FDA, Pfizer misrepresented the drug’s safety and effectiveness.

VIOLATIONS OF LAW
10.
11.

The allegations contained in paragraphs 1-9 are incorporated herein by reference.
The Defendant, in the course of advertising, soliciting, selling, promoting and

distributing the prescription drug Geodon, has engaged in a course of trade or commerce which
constitutes unfair or deceptive acts or practices, and which are therefore unlawful under § 207 of
the UTPA by misrepresenting Geodon’s safety and efficacy.
PRAYER FOR RELIEF
WHEREFORE, the Plaintiff prays that this honorable Court enter ah Order:
A.

Issuing a permanent injunction prohibiting Defendant, its agents, employees*

and all other persons and entities, corporate or otherwise, in active concert or participation
with any o f them, from engaging in unfair or deceptive conduct in violation of 5 M.R.S.A.
§207;
B.

Ordering Defendant to pay all costs for the prosecution and investigation o f this

action, as provided by 5 M.R.S.A. § 209 and 14 M.R.S.A. § 1522(1)(A);
C.

Ordering Defendant to pay civil penalties o f $10,000 for each and every

intentional violation of 5 M.R.S.A. § 207; and
D.

Granting such other and further relief as the Court deems equitable and proper.
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D ated: Septem ber 2 ,2 0 0 9

R espectfully submitted,

JANET T. MILLS
ATTORNEY GENERAL

CAROLYN4A. SILSBY, Bar N o.
ASSISTANT ATTORNEY GENEI
Office of the Maine Attorney General
6 State House Station
Augusta, ME 04333-0003
(207) 626-8829
Carolvn.silsbv@maine.gov
ATTORNEYS ¡FOR THE STATE OF MAINE
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SUPERIOR COURT
CIVIL ACTION
DOCKET NO. -CV-Q9=257get -

STATE OF MAINE
KENNEBEC, SS

)
)
)
)
)
)
)
)
)
I

STATE OF MAINE,
Plaintiff
V.

PFIZER INC.,
Defendant.

O R D E R O N A SSE N T E D -T O M O T IO N
T O A M E N D C O N SE N T JU D G M E N T

Igment o f September 9, 2009 in this

Upo;

D.

matter, withe

aph 17 o f the Consent Judgment shall

Accor
be modified ar.

- ¡To»

V

^

Isfers o f value (whether in cash or in
“Paymt
luding, for example, honoraria
kind) mt
iging, travel and other expenses)
payment
rs, participating in speaker training,
made in (
or serving
, ju m e n ts or compensation for services rendered;
relating to research; payments relating to education; and payment
grants; fee _ „
or reimbursement for food, entertainment, gifts, trips or travel, product(s)/item(s)
provided for less than fair market value, or other economic benefit paid or transferred.
The term also includes all payments or transfers o f value made to Related Entities on
behalf of, at the request of, for the benefit or use of, or under the name o f a physician for
whom Pfizer would otherwise report a Payment if made directly to the physician. The
term “Payments” includes any Payments made, directly or indirectly, by Pfizer to a
physician or Related Entity in connection with, or under the auspices of, a co-promotion
arrangement. The term “Payments” does not include: i) samples o f drug products that
meet the definition set forth in 21 C.F.R. § 203.3(i), or ii) discounts, rebates, or other
pricing terms. Only for purposes o f the reporting o f Payments on March 31, 2011, the
term “Payments” does not include: i) individual Payments o f less than $25 per instance,
or ii) aggregate Payments in a year to a physician or Related Entity o f less than $500. Beginning with the March 31, 2012 report and all reports thereafter, individual Payments )
o f less than $10 per instance to any individual physician or Related Entitv
k*-

1

Entered on the Docket: f
/%
Copies sent via Mall ✓ Electronically

excluded from the Payment amounts listed in the applicable report, unless the sum of
Payments to that individual physician or Related Entity in a calendar year exceeds $100.

All other terms and conditions set forth in the Consent Judgment remain unchanged.
The Clerk is specifically directed pursuant to Rule 79(a) o f the Maine Rules o f Civil
Procedure to enter this Order on the Civil Docket by notation incorporating it by reference.

Dated:
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R egional O ffices:
84 H arlow St , 2nd F loor
B angor , M aine.04401
T ed (207) 941-3070
F ax : (207) 941-3075

Ja n e t T. M ills

44 O ak Street , 4 th F loor
P ortland , M aine . 04101-3014

ATTORNEY GENERAL

T e l (207) 822-0260
F ax : (207) 822-0259
TDD: (877) 428-8800

TEL: (207)626-8800
TTY: 1-888-577-6690

S tate o f M a in e
O f f ic e o f t h e A t t o r n e y G e n e r a l
6 S t a t e H o u s e S t a t io n
A u g u s t a , M a in e 04333-0006

14 A ccess H ighway, Ste .1
Caribou, M aine,04736
T e l (207) 496-3792
Fax : (207) 496-3291
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BY HAND DELIVERY
M ich ele L um bert, C lerk
MAINE SUPERIOR COURT
K en n eb ec C o u n ty C o u r th o u se •
9 5 S ta te S treet
A u g u sta , M aine 0 4 3 3 0
RE:

•

State o f Maine v. P fizer , Inc.
D o ck et No. C V -2 0 0 9 -

D ea r M s. Lum bert:
E n c lo se d for filing in th e a b o v e-referen ced m a tter p le a se find Pfizer’s
o rig in a l c o r p o r a te /n a tio n a l c o u n s e l sig n a tu r e p a g e for th e p rev io u sly filed
C o n s e n t J u d g m e n t.
T h an k y o u for y o u r a s s is ta n c e .
S in cerely ,
/?

A s s is ta n t A ttorney G eneral
C A S /g a c
E n c lo su r e s
cc: R u s se ll B. Pierce, J r ., E sq .
D a n ielle Pelfrey D u r y e a , E sq .

I •h I M r 1

PAN U

For Pfizer Inc.:

R „.

Douglas M. Lankier
Senior Vice President
And Chief Compliance Officer
Pfizer Inc.
Date:_______________________________

O'

By:

Brien T. O’Connor
Ropes & Gray LLP
One International Place
Boston, MA 02110
Date:

DLA Piper LLP (US)
33 Arch Street, 26th Floor
Boston, MA 02110
Date: ‘V é '/à j
~ ri

